Method for producing nucleic acid oligomer
Patent Information
- Application Number
- JP2024510168
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Filing Date
- 2024-10-21
- Publication Date
- 2024-12-03
- Estimated Expiration
- 2043-03-20
AI Technical Summary
The existing methods for producing nucleic acid oligomers through solid phase synthesis are inefficient due to unsatisfactory purity and multi-step processes, particularly in the deprotection of hydroxyl groups in ribose-containing nucleic acid oligomers.
Contacting nucleic acid oligomers with fluoride ions in the presence of a radical reaction inhibitor to efficiently deprotect the hydroxyl group of ribose, improving the synthesis process and increasing the purity of the produced oligomers.
This method enhances the efficiency and purity of nucleic acid oligomer production by effectively removing protecting groups, leading to improved nucleic acid oligomer synthesis.
Smart Images

Figure 2023182274000001 
Figure 2023182274000002 
Figure 2023182274000003
Abstract
Description
Method for producing nucleic acid oligomers
[0001] This patent application claims priority under the Paris Convention to and the benefit of Japanese Patent Application No. 2022-047341 (filed March 23, 2022), the entire contents of which are incorporated herein by reference. The present invention relates to a method for producing a nucleic acid oligomer containing ribose, and more specifically, to a method for deprotecting the protecting group of the hydroxyl group of ribose contained in the nucleic acid oligomer.
[0002] In recent years, there has been growing interest in the application of nucleic acid oligomers in the medical field, including antisense nucleic acids, aptamers, ribozymes, and nucleic acids that induce RNA interference (RNAi), such as siRNA, which are called nucleic acid drugs.
[0003] Nucleic acid oligomers can be synthesized by solid-phase synthesis, which uses nucleoside phosphoramidites (hereinafter referred to as "amidites") as starting materials. Nucleic acid oligomers synthesized by extending nucleic acids on a solid support are cleaved from the solid support, and then, for nucleic acid oligomers containing ribose, the protecting group on the 2'-hydroxyl group of the ribose is removed by deprotection to produce the desired nucleic acid oligomer. The purity of the nucleic acid oligomers synthesized in this manner is not necessarily satisfactory because they undergo multiple steps, such as the extension reaction step of the nucleic acid on the solid support, the cleavage step from the solid support, and the deprotection step of each protecting group, and the synthesis is inefficient (Patent Documents 1 and 2).
[0004] International Publication No. WO 2006 / 022323 International Publication No. WO 2013 / 027843
[0005] An object of the present invention is to provide a method for efficiently producing a nucleic acid oligomer.
[0006] As a result of extensive research to achieve the above object, the present inventors have discovered that the protecting groups on the hydroxyl groups of ribose in a nucleic acid oligomer can be efficiently deprotected by contacting the nucleic acid oligomer with fluoride ions in the presence of a radical reaction inhibitor. As a result, an efficient method for producing a nucleic acid oligomer can be provided.
[0007] The present invention has been completed based on these findings and includes, but is not limited to, the following aspects.
[0008] 1. In the presence of a radical reaction inhibitor, a compound represented by the following formula (3): (In the formula, G 4 represents a protecting group for a hydrogen atom or a hydroxyl group; 9 represents an ammonium ion, an alkylammonium ion, an alkali metal ion, a hydrogen ion or a hydroxyalkylammonium ion; c are each independently the same or different and represent a nucleobase, R is each independently the same or different and represents a hydrogen atom, a fluorine atom, or an OQ group, Q is each independently the same or different and represents a tert-butyldimethylsilyl group, a methyl group, a 2-methoxyethyl group, a methylene group bonded to the carbon atom at the 4' position of ribose, an ethylene group bonded to the carbon atom at the 4' position of ribose, an ethylidene group bonded to the carbon atom at the 4' position of ribose, or a group represented by the following formula (1): (wherein, the bond marked with * represents a bond to the oxygen atom of the OQ group, and n represents an integer of 0 or greater), each Y is independently the same or different and represents an oxygen atom or a sulfur atom, m represents an integer of 2 or greater and 300, W and X are defined as either (a) or (b) below, (a) when W is a hydroxyl group, X has the same definition as the R group described above. (b) when X is a hydroxyl group, W represents an OV group, and V represents a tert-butyldimethylsilyl group or a group of the formula (1) described above, with the proviso that at least one group of the R, W, and X represents a hydroxyl group protected with a protecting group of the formula (1) described above. and when m is an integer of 3 or more, the nucleic acid oligomer represented by formula (3) is a nucleic acid oligomer in which non-nucleotide linkers may be incorporated in place of p nucleotides (where p is a positive integer satisfying the formula: m-1>p) between the 5'-terminal and 3'-terminal nucleotides.), characterized by contacting a nucleic acid oligomer represented by the following formula (4): (wherein R' are each independently the same or different and represent a hydroxyl group, a hydrogen atom, a fluorine atom, a methoxy group, a 2-methoxyethyl group, or an OQ' group; Q' are each independently the same or different and represent a methylene group bonded to the carbon atom at the 4' position of ribose, an ethylene group bonded to the carbon atom at the 4' position, or an ethylidene group bonded to the carbon atom at the 4' position; and 4 , G 9 , Y, B c and m are defined as in the formula (3), 0 is a hydroxyl group, and X 0has the same definition as the R' group. When m is an integer of 3 or greater, the nucleic acid oligomer represented by formula (4) is a nucleic acid oligomer in which a non-nucleotide linker may be incorporated in place of p nucleotides (where p is a positive integer satisfying the formula: m-1>p) between each 5'-terminal and 3'-terminal nucleotide.) (Hereinafter referred to as the "production method of the present invention" or the "production method of this embodiment" in this specification). 2. The production method according to the preceding item 1, wherein n in formula (1) is 0 or 1. 3. The production method according to the preceding item 1, wherein n in formula (1) is 0. 4. The production method according to the preceding item 1, wherein n in formula (1) is 1. 5. The production method according to any one of the preceding items 1 to 4, wherein the non-nucleotide linker is a linker consisting of an amino acid skeleton. 6. 6. The production method according to item 5 above, wherein the linker comprising an amino acid skeleton is a linker having a structure represented by the following formula (A14-1), (A14-2), or (A14-3): (In the formula, 5' and 3' represent the 5'-end and 3'-end of the nucleic acid oligomer, respectively.) 7. W is a hydroxyl group, X is an R group, and W 0 is a hydroxyl group, and X 0 is an R' group. 8. The method for production according to any one of items 1 to 6 above, wherein the fluoride ion source is tetraalkylammonium fluoride. 9. The method for production according to any one of items 1 to 8 above, wherein the fluoride ion source is tetra-n-butylammonium fluoride. 10. The method for production according to any one of items 1 to 9 above, wherein the radical reaction inhibitor is a radical chain initiation inhibitor, a radical scavenger, or a peroxide decomposer. 11. The method for production according to any one of items 1 to 9 above, wherein the radical reaction inhibitor is a radical scavenger. 12. The method for production according to item 11 above, wherein the radical scavenger is a phenolic antioxidant or a hindered amine light stabilizer. 13. The method for production according to item 11 above, wherein the radical scavenger is a phenolic antioxidant. 14. 14. The method according to item 12 or 13 above, wherein the phenolic antioxidant is a compound represented by the following formula (8): (In the formula, R 10 , R 11 , R 12 , and R 13 are the same or different and each represent a chain hydrocarbon group, a carbocyclyl group, a heterocyclyl group, an alkoxy group, an alkylsulfanyl group (the chain hydrocarbon group, the carbocyclyl group, the heterocyclyl group, the alkoxy group, and the alkylsulfanyl group may have one or more substituents), SiR 51 R 52 R 53 , amide group, C(O)R 61 , O.C.(O.)R 61 , a hydroxyl group, or a hydrogen atom; R 51 , R 52 and R 53 are the same or different and represent an alkyl group, an alkoxy group, or a hydrogen atom; R 61 represents a chain hydrocarbon group.) 15. The production method according to the above item 12, wherein the radical scavenger is a hindered amine light stabilizer. 16. The production method according to the above item 12, 14, or 15, wherein the hindered amine light stabilizer is a compound represented by formula (12). (In the formula, R 14 is OC(O)R 20 , N.H.R. 20 or a hydrogen atom, R 19 represents an alkyl group, an alkoxy group, an oxygen free radical, a hydroxyl group, or a hydrogen atom; R 15 , R 16 , R 17 , and R 18 are the same or different and represent an alkyl group or a hydrogen atom; R 20 represents a chain hydrocarbon group, a carbocyclyl group, a heterocyclyl group, an alkoxy group, or an alkylsulfanyl group (the chain hydrocarbon group, the carbocyclyl group, the heterocyclyl group, the alkoxy group, or the alkylsulfanyl group may have one or more substituents), SiR 54 R 55 R 56 , an amide group, a hydroxyl group, or a hydrogen atom; R 54 , R 55 and R 56are the same or different and represent an alkyl group, an alkoxy group, or a hydrogen atom.) 17. The production method according to any one of items 1 to 9 above, wherein the radical reaction inhibitor is a peroxide decomposer. 18. The production method according to item 17 above, wherein the peroxide decomposer is a phosphorus-based antioxidant or a sulfur-based antioxidant. 19. The production method according to item 17 above, wherein the peroxide decomposer is a phosphorus-based antioxidant. 20. The production method according to item 17 above, wherein the peroxide decomposer is a sulfur-based antioxidant. 21. The production method according to any one of items 1 to 9 above, wherein the radical reaction inhibitor is a radical chain initiation inhibitor. 22. The production method according to item 21 above, wherein the radical chain initiation inhibitor is a metal deactivator or an ultraviolet absorber. 23. The production method according to item 21 above, wherein the radical chain initiation inhibitor is a metal deactivator. 24. The production method according to item 21 above, wherein the radical chain initiation inhibitor is an ultraviolet absorber. 25. 25. The method for production according to any one of items 1 to 24 above, wherein the amount of radical reaction inhibitor used is 9 moles or less per mole obtained by multiplying the number of moles of the nucleic acid oligomer represented by formula (3) by the number of times R in formula (3) is a group represented by formula (1). 26. The method for production according to any one of items 1 to 25 above, wherein the proportion of protecting groups of formula (1) among R, W, and X in the nucleic acid oligomer represented by formula (3) is 10% or more, and the nucleic acid chain length is 10 chain lengths or more.
[0009] The present invention provides an efficient method for producing nucleic acid oligomers, which is expected to improve the purity of the produced nucleic acid oligomers.
[0010] As a mode for carrying out the present invention, an embodiment will be shown and described, but the present invention is not limited to the following embodiment.
[0011] The substituents will now be described. A halogen atom refers to a fluorine atom, chlorine atom, bromine atom, or iodine atom. When a substituent is substituted with two or more halogen atoms or substituents, these halogen atoms or substituents may be the same or different. The chain hydrocarbon group refers to an alkyl group, an alkenyl group, or an alkynyl group. Examples of alkyl groups include a methyl group, an ethyl group, a propyl group, an isopropyl group, a 1,1-dimethylpropyl group, a 1,2-dimethylpropyl group, a 1-ethylpropyl group, a butyl group, a sec-butyl group, an isobutyl group, a tert-butyl group, a pentyl group, and a hexyl group. Examples of alkenyl groups include a vinyl group, a 1-propenyl group, a 2-propenyl group, a 1-methyl-1-propenyl group, a 1-methyl-2-propenyl group, a 1,2-dimethyl-1-propenyl group, a 1-ethyl-2-propenyl group, a 3-butenyl group, a 4-pentenyl group, and a 5-hexenyl group. Examples of alkynyl groups include ethynyl, 1-propynyl, 2-propynyl, 1-methyl-2-propynyl, 1,1-dimethyl-2-propynyl, 1-ethyl-2-propynyl, 2-butynyl, 4-pentynyl, and 5-hexynyl. Examples of alkoxy groups include methoxy, ethoxy, propoxy, isopropoxy, butoxy, tert-butoxy, pentyloxy, hexyloxy, and octyloxy. Examples of alkylsulfanyl groups include methylsulfinyl, ethylsulfinyl, propylsulfinyl, isopropylsulfinyl, butylsulfinyl, tert-butylsulfinyl, pentylsulfinyl, hexylsulfinyl, and octylsulfinyl. Examples of alkenyloxy groups include 2-propenyloxy groups, 2-butenyloxy groups, and 5-hexenyloxy groups. Examples of alkynyloxy groups include 2-propynyloxy groups, 2-butynyloxy groups, and 5-hexynyloxy groups. A carbocyclyl group refers to a cyclic aromatic carbocyclic group or an alicyclic hydrocarbon group. Examples of aromatic carbocyclic groups include a phenyl group and a naphthyl group.Alicyclic hydrocarbon groups include cycloalkyl groups, cycloalkenyl groups, and the like. Examples of cycloalkyl groups include cyclopropyl groups, cyclobutyl groups, cyclopentyl groups, cyclohexyl groups, and cycloheptyl groups. Examples of cycloalkenyl groups include cyclopropenyl groups, cyclobutenyl groups, cyclopentenyl groups, cyclohexenyl groups, and cycloheptenyl groups. A heterocyclyl group refers to a cyclic group having one or more heteroatoms as ring-constituting atoms, and includes aromatic heterocyclic groups and non-aromatic heterocyclic groups. Examples of heterocyclyl groups include pyrrolyl, furyl, thienyl, pyrazolyl, imidazolyl, triazolyl, tetrazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, oxadiazolyl, thiadiazolyl, pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl, triazinyl, tetrazinyl, pyrrolidinyl, imidazolinyl, imidazolidinyl, piperidinyl, tetrahydropyrimidinyl, hexahydropyrimidinyl, piperazinyl, oxazolidinyl, isoxazolidinyl, 1,3-oxazinanyl, morpholinyl, thiazolidinyl, isothiazolidinyl, 1,3-thiazinanyl, and thiomorpholinyl.
[0012] Hereinafter, a method for producing a nucleic acid oligomer represented by formula (4) in which the protecting group of formula (1) below has been deprotected by contacting a nucleic acid oligomer represented by formula (3) with fluoride ions in the presence of a radical reaction inhibitor will be described.
[0013] In formula (1), n is any integer of 0 or more, more preferably an integer of 0 to 3, more preferably an integer of 0 to 2, even more preferably 0 or 1, and particularly preferably 1.
[0014] At least one of the groups R, W, and X in formula (3) represents a hydroxyl group protected by a protecting group of formula (1). The proportion of formula (1) among R, W, and X may be 1% or more, more preferably 5% or more, more preferably 10% or more, more preferably 20% or more, more preferably 30% or more, more preferably 40% or more, more preferably 50% or more, more preferably 60% or more, more preferably 70% or more, more preferably 80% or more, more preferably 90% or more, and even more preferably 95% or more. In addition, the nucleic acid chain length (base length, nucleic acid polymerization number, dimer) to be synthesized is preferably 10 or more, more preferably 20 or more, more preferably 30 or more, more preferably 40 or more, and even more preferably 50 or more.
[0015] In the step of deprotecting the protecting group represented by formula (1), a tetraalkylammonium fluoride is typically used as a fluoride ion source. Examples of tetraalkylammonium fluorides include tetrabutylammonium fluoride and tetramethylammonium fluoride. Among these, tetrabutylammonium fluoride (TBAF) is more preferred. The amount of fluoride ions used is usually 1 to 1,000 mol, preferably 1 to 500 mol, more preferably 2 to 200 mol, and more preferably 4 to 100 mol per mol of protecting group to be removed.
[0016] Examples of radical reaction inhibitors include radical chain initiation inhibitors, radical scavengers, and peroxide decomposers.
[0017] Examples of radical chain initiation inhibitors include metal deactivators, ultraviolet absorbers, quenchers, etc. Examples of metal deactivators include amide compounds and hydrazide compounds, such as n-octanohydrazide, succinic acid dihydrazide, 2-hydroxy-N-1H-1,2,4-triazol-3-ylbenzamide, N'1,N'12-Bis(2-hydroxybenzoyl)dodecanedihydrazide, N,N'-Bis[3-(3,5-di-tert-butyl-4-hydroxyphenyl)propionyl]hydrazine, and 1,3,5-triazine-2,4,6-triamine. Examples of the ultraviolet absorber include triazole compounds, triazine compounds, and benzophenone compounds. Specific examples include benzophenone, 2-(2H-Benzotriazol-2-yl)-4,6-bis(1-methyl-1-phenylethyl)phenol, 2-(2H-Benzotriazol-2-yl)-4-(1,1,3,3-tetramethylbutyl)phenol, 2,2'-Methylenebis[6-(2H-benzotriazol-2-yl)-4-(1,1,3,3-tetramethylbutyl)phenol], 2-(2H-Benzo Examples of suitable quenchers include 2-(triazol-2-yl)-p-cresol, 2-(5-chloro-2H-benzotriazol-2-yl)-6-tert-butyl-4-methylphenol, 2-(4,6-Diphenyl-1,3,5-triazin-2-yl)-5-[2-(2-ethylhexanoyloxy)ethoxy]phenol, 2,4,6-tris(2-hydroxy-4-hexyloxy-3-methylphenyl)-1,3,5-triazine, and [2-hydroxy-4-(octyloxy)phenyl](phenyl)methanone. Examples of suitable quenchers include organic nickel compounds. Specific examples include bis(1,2-bis(2-methoxyphenyl)-1,2-ethylenedithiolato)nickel complex, Raney nickel, tetracarbonickel, and NiX. 2 (PR3 ) wherein X represents a halogen atom, and PR 3 represents a phosphine ligand (for example, a tertiary phosphine such as triphenylphosphine), etc.].
[0018] Examples of the radical scavenger include phenolic antioxidants and hindered amine light stabilizers (HALS).
[0019] Examples of the phenol-based antioxidant include hindered phenol-based compounds, semi-hindered phenol-based compounds, and less hindered phenol-based compounds.
[0020] Examples of the phenol-based antioxidant include the following compounds, but any compound generally used as a phenol-based antioxidant can be used in this embodiment.
[0021] A compound represented by the following formula (8):
[0022] In formula (8), R 12 The compound in which is a hydrogen atom can also be represented by the following formula (8a).
[0023] In formula (8), R 11 The compound in which is a hydrogen atom can also be represented by the following formula (8b).
[0024] In formula (8), formula (8a) and formula (8b), R 10 is preferably a tert-butyl group, a sec-butyl group, or a methyl group, and R 11 and R 12 are the same or different and are preferably a tert-butyl group, a sec-butyl group, a methyl group, or a hydrogen atom, and R 13 is preferably a tert-butyl group, a sec-butyl group, a methyl group, a hydroxyl group, or a hydrogen atom.
[0025] A compound represented by the following formula (13a): (In the formula, R 10 , R 11 , R12 is the same as that in formula (8), and R 10‘ , R 11’ , R 12‘ , R 21 , R 22 , and R 23 are the same or different and each represent a chain hydrocarbon group, a carbocyclyl group, a heterocyclyl group, an alkoxy group, an alkylsulfanyl group (the chain hydrocarbon group, the carbocyclyl group, the heterocyclyl group, the alkoxy group, and the alkylsulfanyl group may have one or more substituents), SiR 51 R 52 R 53 , amide group, C(O)R 61 , O.C.(O.)R 61 , a hydroxyl group, or a hydrogen atom; R 24 is an oxygen atom, a sulfur atom, S(O), or S(O) 2 indicates R 25 represents an oxygen atom or a sulfur atom, n 1 , n 2 , n 3 , and n 4 Each represents an arbitrary 0 or positive integer, and the (CR 21 R 22 ) n1 , (NR 23 ) n2 , (R 24 ) n3 , and (C=R 25 ) n4 The order of is arbitrary, and if there are multiple of each, they do not have to be consecutive.)
[0026] A compound represented by the following formula (13b): (In the formula, the definitions of the symbols are the same as those in formula (13a).)
[0027] A compound represented by the following formula (13c): (In the formula, R 10 , R 11 , R 12 , R 10‘ , R 11’ , R 12’ , and n 1 is the same as that in formula (13a), and R 10”, R 11” , R 12” , R 21’ , R 22‘ , R 21” , and R 22” are the same or different and each represent a chain hydrocarbon group, a carbocyclyl group, a heterocyclyl group, an alkoxy group, an alkylsulfanyl group (the chain hydrocarbon group, the carbocyclyl group, the heterocyclyl group, the alkoxy group, and the alkylsulfanyl group may have one or more substituents), SiR 51 R 52 R 53 , amide group, C(O)R 61 , O.C.(O.)R 61 , a hydroxyl group, or a hydrogen atom; n 1’ and n 1” Each of the symbols represents an arbitrary 0 or positive integer.
[0028] A compound represented by the following formula (13d): (In the formula, the definitions of the symbols are the same as those in formula (13c).)
[0029] A compound represented by the following formula (13e): (In the formula, R 10 , R 11 , R 12 , R 10‘ , R 11’ , R 12’ , R 10” , R 11” , R 12” , R 21’ , R 22‘ , R 21” , R 22” , n 1 , n 1’ , and n 1” is the same as that in formula (13c), and R 10”’ , R 11”’ , R 12”’ , R 21’” , and R 22‘” are the same or different and each represent a chain hydrocarbon group, a carbocyclyl group, a heterocyclyl group, an alkoxy group, an alkylsulfanyl group (the chain hydrocarbon group, the carbocyclyl group, the heterocyclyl group, the alkoxy group, and the alkylsulfanyl group may have one or more substituents), SiR51 R 52 R 53 , amide group, C(O)R 61 , O.C.(O.)R 61 , a hydroxyl group, or a hydrogen atom; n 1”’ indicates any 0 or positive integer.)
[0030] A compound represented by the following formula (13f): (In the formula, R 10 , R 11 , R 12 , R 10‘ , R 11’ , R 12’ , R 10” , R 11” , R 12” , R 21’ , R 22‘ , R 21” , R 22” , n 1 , n 1’ , and n 1” is the same as that in formula (13c), and R 21”” , R 22”” , and R 23”” are the same or different and each represent a chain hydrocarbon group, a carbocyclyl group, a heterocyclyl group, an alkoxy group, an alkylsulfanyl group (the chain hydrocarbon group, the carbocyclyl group, the heterocyclyl group, the alkoxy group, and the alkylsulfanyl group may have one or more substituents), SiR 51 R 52 R 53 , amide group, C(O)R 61 , O.C.(O.)R 61 , a hydroxyl group, or a hydrogen atom.)
[0031] R 10 , R 11 , R 12 , R 13 , R 10‘ , R 11’ , R 12‘ , R 21 , R 22 , R 23 , R 10” , R 11” , R 12” , R 21’ , R 22‘ , R 21”, R 22” , R 10”’ , R 11”’ , R 12”’ , R 21’” , R 22‘” , R 21”” , R 22”” , and R 23”” In the above, examples of the substituent that the chain hydrocarbon group, carbocyclyl group, heterocyclyl group, alkoxy group, and alkylsulfanyl group may have include a halogen atom, a carbocyclyl group, a heterocyclyl group, a hydroxyl group, an amino group, an alkoxy group, a sulfanyl group, an alkylsulfanyl group, SiR 51 R 52 R 53 , O(SiR 51 R 52 R 53 ), C(O)R 61 , O.C.(O.)R 61 , and P(O)(OR 62 ) 2 Here, R 62 represents a chain hydrocarbon group.
[0032] Specific examples of phenolic antioxidants include 2,6-di-tert-butyl-p-cresol, 4-sec-butyl-2,6-di-tert-butylphenol, 6-tert-butyl-2,4-xylenol, 4,6-di-tert-butyl-m-cresol, 1,4-dihydroxybenzene, 2,6-Di-tert-butyl-4-ethylphenol, 4,4'-Dihydroxy-3,3',5,5'-tetraisopropylbiphenyl, 3-(3,5-Di-tert-butyl-4-hydroxyphenyl)-N'-[3-(3,5-di-tert-butyl-4-hydroxyphenyl)propanoyl]propanehydrazide, and Methyl 3-(3,5-Di-tert-butyl-4-hydroxyphenyl)propionate, 2,2'-Methylenebis(6-tert-butyl-4-ethylphenol), 2,2'-Methylenebis[6-(1-methylcyclohexyl)-p-cresol], 1,3,5-Tris( 3,5-di-tert-butyl-4-hydroxybenzyl)-1,3,5-triazinane-2,4,6-trione, 2,5-Bis(1,1,3,3-tetramethylbutyl)hydroquinone, 2,5-Di-tert-butylhydroquinone, 4,4'-Butylideneb is(6-tert-butyl-m-cresol), 4-(Hexyloxy)-2,3,6-trimethylphenol, N,N'-(Hexane-1,6-diyl)bis[3-(3,5-di-tert-butyl-4-hydroxyphenyl)propanamide], 2,2',6,6'-Tetra-ter t-butyl-4,4'-dihydroxybiphenyl, 2,5-Di-tert-amylhydroquinone, 2,4-Bis[(dodecylthio)methyl]-6-methylphenol, 4-[[4,6-Bis(n-octylthio)-1,3,5-triazin-2-yl]amino]-2,6-di-tert-butylphenol、Galvinoxyl Free Radical、Pentaerythritol Tetrakis[3-(3,5-di-tert-butyl-4-hydroxyphenyl)propionate]、Hexadecyl 3,5-Di-tert-butyl-4-hydroxybenzoate、4,4'-Thiobis(6-tert-butyl-m-cresol)、3,3',5,5'-Tetra-tert-butyl-4,4'-stilbenequinone、2,4,6-Tris(3',5'-di-tert-butyl-4'-hydroxybenzyl)mesitylene、2,6-Di-tert-butyl-4-methoxyphenol、2,2'-Methylenebis(6-cyclohexyl-p-cresol)、[Oxalylbis(azanediyl)]bis(ethane-2,1-diyl) Bis[3-(3,5-di-tert-butyl-4-hydroxyphenyl)propanoate]、3,6-Dihydroxybenzonorbornane、2-Methyl-4,6-bis[(n-octylthio)methyl]phenol、2,6-Di-tert-butylphenol、2,4,8,10-Tetraoxaspiro[5.5]undecane-3,9-diylbis(2-methylpropane-2,1-diyl) Bis[3-[3-(tert-butyl)-4-hydroxy-5-methylphenyl]propanoate]、Diethyl 3,5-Di-tert-butyl-4-hydroxybenzylphosphonate、2,4,6-Tris(2,4-dihydroxyphenyl)-1,3,5-triazine、2-tert-Butyl-6-(3-tert-butyl-2-hydroxy-5-methylbenzyl)-4-methylphenyl Acrylate、Triethylene Glycol Bis[3-(3-tert-butyl-4-hydroxy-5-methylphenyl)propionate]、3-(3,5-Di-tert-butyl-4-hydroxyphenyl)propionic acid, Stearyl 3-(3,5-Di-tert-butyl-4-hydroxyphenyl)propionate, 4,6-Di-tert-butylresorcinol, 1,3,5-tris(3,5-di-tert-butyl-4-hydroxybenzyl)-1,3,5-triazine-2,4 ,6(1H,3H,5H)-trione, 4,4',4''-(1-methylpropanyl-3-ylidene)tris(6-tert-butyl-m-cresol), 6,6'-di-tert-butyl-4,4'-butylidenedi-m-cresol, Octadecyl 3-(3,5-di-tert-butyl-4-hydroxyphenyl)propionate, Pentaerythritol tetrakis[3-(3,5-di-tert-butyl-4-hydroxyphenyl)propionate], 3,9-Bis{2-[3-(3-tert-butyl-4-hydroxy-5-methylphenyl)propionyloxy]-1,1-dim ethylethyl}-2,4,8,10-tetraoxaspiro[5.5]undecane, or 1,3,5-tris(3,5-di-tert-butyl-4-hydroxyphenylmethyl)-2,4,6-trimethylbenzene. ,
[0033] Examples of hindered amine light stabilizers (HALS) include the following compounds, but any compounds generally used as phenolic antioxidants can be used in this embodiment.
[0034] A compound represented by the following formula (12): In formula (12), R 15 , R 16 , R 17 , and R 18 is preferably a methyl group.
[0035] In formula (12), R 15 , R 16 , R17 , and R 18 The compound in which is a methyl group can also be represented by the following formula (12A).
[0036] A compound represented by the following formula (12a): (In the formula, R 15 , R 16 , R 17 , R 18 , and R 19 is the same as that in the formula (12), and R 19‘ represents an alkyl group, an alkoxy group, an oxygen free radical, a hydroxyl group, or a hydrogen atom; R 15’ , R 16‘ , R 17’ , R 18‘ , R 26 , R 27 , R 28 , and R 29 are the same or different and represent an alkyl group or a hydrogen atom; n 5 indicates any 0 or positive integer.)
[0037] A compound represented by the following formula (12b): (In the formula, the definitions of the symbols are the same as those in the formula (12a) above.)
[0038] A compound represented by the following formula (12c): (In the formula, R 15 , R 16 , R 17 , R 18 , R 19 , R 15’ , R 16‘ , R 17’ , R 18‘ , R 19‘ , R 28 , and R 29 is the same as that in formula (12a), and R 30 , R 31 , R 32 , and R 33 are the same or different and represent an alkyl group or a hydrogen atom.
[0039] R 20In the above, examples of the substituent that the chain hydrocarbon group, carbocyclyl group, heterocyclyl group, alkoxy group, and alkylsulfanyl group may have include a halogen atom, a carbocyclyl group, a heterocyclyl group, a hydroxyl group, an amino group, an alkoxy group, a sulfanyl group, an alkylsulfanyl group, SiR 54 R 55 R 56 , O(SiR 51 R 52 R 53 ), C(O)R 63 , O.C.(O.)R 63 , and P(O)(OR 64 ) 2 Here, R 63 represents a chain hydrocarbon group, and R 62 represents a chain hydrocarbon group. 15 , R 16 , R 17 , R 18 , R 19 , R 15’ , R 16‘ , R 17’ , R 18‘ , R 26 , R 27 , R 28 , and R 29 The alkyl group in the formula (I) may have a substituent, such as a phenyl group which may have a substituent (for example, an alkyl group, a hydroxyl group).
[0040] Specific examples of the hindered amine light stabilizer (HALS) include bis(2,2,6,6-tetramethyl-4-piperidyl) sebacate, 2,2,6,6-tetramethyl-4-piperidyl methacrylate, 2,2,6,6-tetramethylpiperidine 1-oxyl free radical (TEMPO free radical), N,N'-Bis(2,2,6,6-tetramethylpiperidin-4-yl)hexane-1,6-diamine, 2,2,6,6-tetramethylpiperidine 1-oxyl, Bis(2,2,6,6-tetramethyl-4-piperidyl-1-oxyl) Sebacate, Bis(1,2,2,6,6-pentamethyl-4-piperidyl) Sebacate, and Bis(2,2,6,6-tetramethyl-4-piperidyl) Sebacate, 1,2,2,6,6-Pentamethyl-4-piperidyl Methacrylate, N 1 ,N 3-Bis(2,2,6,6-tetramethylpiperidin-4-yl)isophthalamide、Bis(1,2,2,6,6-pentamethyl-4-piperidyl) Butyl(3,5-di-tert-butyl-4-hydroxybenzyl)malonate、2,2,6,6-Tetramethyl-4-piperidyl Methacrylate、Tetrakis(1,2,2,6,6-pentamethyl-4-piperidyl) butane-1,2,3,4-tetracarboxylate、Tetrakis(2,2,6,6-tetramethyl-4-piperidyl) butane-1,2,3,4-tetracarboxylate、1,2,3,4-Butanetetracarboxylic acid, tetramethyl ester, reaction products with 1,2,2,6,6-pentamethyl-4-piperidinol and β,β,β',β'-tetramethyl-2,4,8,10-tetraoxaspiro[5.5]undecane-3,9-diethanol、1,2,3,4-Butanetetracarboxylic acid, tetramethyl ester, reaction products with 2,2,6,6-tetramethyl-4-piperidinol and β,β,β',β'-tetramethyl-2,4,8,10-tetraoxaspiro[5.5]undecane-3,9-diethanol, Bis(1,2,2,6,6-pentamethyl-4-piperidyl) sebacate, Bis(2,2,6,6-tetramethyl-4-piperidyl) sebacate, Bis(1-undecanoxy-2,2,6,6-tetramethylpiperidin-4-yl)carbonate, 1,2,2,6,6-Pentamethyl-4-piperidyl methacrylate, 2,2,6,6-Tetramethyl-4-piperidyl methacrylate, reaction mass of: 2,2,6,6-tetramethylpiperidin-4-yl hexadecanoate 2,2,6,6-tetramethylpiperidin-4-yl octadecanoate, or 2,2,6,6-tetramethylpiperidin-4-yl hexadecanoate 2,2,6,6-tetramethylpiperidin-4-yl octadecanoate, etc. can be mentioned.
[0041] Examples of peroxide decomposers include phosphorus-based antioxidants and sulfur-based antioxidants. Examples of phosphorus-based antioxidants include phosphine compounds and phosphite compounds, and specific examples thereof include triphenylphosphine, triphenyl phosphite, 3,9-Bis(octadecyloxy)-2,4,8,10-tetraoxa-3,9-diphosphaspiro[5.5]undecane, 3,9-Bis(2,6-di-tert-butyl-4-methylphenoxy)-2,4,8,10-tetraoxa-3,9-diphosphaspiro[5.5]undecane, 2,2'-Methylenebis(4,6-di-tert-butylphenyl) 2-ethylhexyl phosphite, Tris(2,4-ditert-butylphenyl) phosphite, Tris(nonylphenyl) phosphite, and Tetra-C12-15-alkyl(propane-2,2-diylbis(4,1-phenylene)). Examples of sulfur-based antioxidants include sulfide compounds, such as dioctadecyl sulfide, 2,2-Bis{[3-(dodecylthio)-1-oxopropoxy]methyl}propane-1,3-diyl bis[3-(dodecylthio)propionate], and Di(tridecyl) 3,3′-thiodipropionate.
[0042] The amount of the radical reaction inhibitor used is usually 10 moles or less, 9 moles or less, 8 moles or less, 6 moles or less, 5 moles or less, 4 moles or less, 3 moles or less, 2 moles or less, 1.5 moles or less, 1.3 moles or less, or 1.1 moles or less, and is 0.001 moles or more, 0.01 moles or more, 0.05 moles or more, 0.1 moles or more, or the ... 0.001 moles or more, 0.01 moles or more, 0.05 moles or more, 0.1 moles or more, or the amount of the radical reaction inhibitor used is 0.001 moles or more, 0.01 moles or more, 0.05 moles or more, 0.1 moles or more, or the amount of the radical reaction inhibitor used is 0.001 moles or more, 0.01 moles or more, 0.05 moles or more, 0.1 moles or more, or the amount of the radical reaction inhibitor used is 0.001 moles or more, 0.01 moles or more, 0.05 moles or more, 0.1 moles or more, or the amount of the radical reaction inhibitor used is 0.001 moles or more, 0.01 moles or more, 0.05 , or 0.5 mol or more, preferably 0.01 to 10 mol, 0.01 to 8 mol, 0.05 to 8 mol, 0.05 to 5 mol, 0.1 to 5 mol, 0.1 to 4 mol, 0.1 to 3 mol, 0.1 to 2 mol, 0.1 to 1.5 mol, 0.1 to 1.3 mol, 0.1 to 1.1 mol, 0.5 to 5 mol, 0.5 to 4 mol, 0.5 to 3 mol, 0.5 to 2 mol, 0.5 to 1.5 mol, 0.5 to 1.3 mol, 0.5 to 1.2 mol, or 0.5 to 1.1 mol. When the radical reaction inhibitor is a hindered amine-based light stabilizer, the amount used is preferably 5 moles or less, 4 moles or less, 3 moles or less, 2 moles or less, 1.5 moles or less, 1.3 moles or less, or 1.1 moles or less, and is 0.001 moles or more, 0. ... The amount is 5 mols or more, 0.1 mols or more, or 0.5 mols or more, and preferably 0.01 to 5 mols, 0.1 to 5 mols, 0.1 to 4 mols, 0.1 to 3 mols, 0.1 to 2 mols, 0.1 to 1.5 mols, 0.1 to 1.3 mols, 0.1 to 1.1 mols, 0.5 to 5 mols, 0.5 to 4 mols, 0.5 to 3 mols, 0.5 to 2 mols, 0.5 to 1.5 mols, 0.5 to 1.3 mols, 0.5 to 1.2 mols, or 0.5 to 1.1 mols.
[0043] In this step, an organic solvent inert to the reaction is usually used. Specific examples include sulfoxide solvents, nitrile solvents, ether solvents, amide solvents, ketone solvents, aliphatic hydrocarbon solvents, ester solvents, aromatic solvents, and mixed solvents of two or more of these. Of these solvents, sulfoxide solvents are preferred. Examples of sulfoxide solvents include dimethyl sulfoxide. Examples of nitrile solvents include acetonitrile and propionitrile. Examples of ether solvents include tetrahydrofuran. Examples of amide solvents include N-methyl-2-pyrrolidone. Examples of ketone solvents include acetone and methyl ethyl ketone. Examples of aliphatic hydrocarbon solvents include hexane and heptane. Examples of ester solvents include methyl acetate and ethyl acetate. Examples of aromatic solvents include toluene and pyridine. Among these, dimethyl sulfoxide or a mixed solvent of dimethyl sulfoxide and acetonitrile is preferred.
[0044] The fluoride ion source, which is a reagent used in the step of deprotecting the protecting group represented by formula (1), is usually dissolved in a solvent and then dehydrated before use. Examples of dehydrating agents include molecular sieves and sulfates, and molecular sieves 4A are preferably used.
[0045] The amount of solvent used is usually 5 to 8,000 L, preferably 50 to 2,000 L, more preferably 100 to 1,600 L per mole of nucleic acid oligomer subjected to the deprotection step.
[0046] If necessary, a compound that reacts with the compound represented by formula (2) below, which is a by-product of this step, to capture the compound can be added. Examples of the capturing compound include nitroalkanes, alkylamines, amidines, thiols, thiol derivatives, and mixtures of two or more of these. Examples of "nitroalkanes" include nitromethane. Examples of "alkylamines" include linear alkylamines having 1 to 6 carbon atoms and cyclic amines having 1 to 8 carbon atoms. Specific examples include methylamine, ethylamine, n-propylamine, n-butylamine, n-pentylamine, n-hexylamine, morpholine, and piperidine. Examples of "amidines" include benzamidine and formamidine. Examples of "thiols" include linear thiols having 1 to 6 carbon atoms. Specific examples include methanethiol, ethanethiol, 1-propanethiol, 1-butanethiol, 1-pentanethiol, and 1-hexanethiol. Examples of "thiol derivatives" include alcohols or ethers having the same or different linear alkylthiol groups having 1 to 6 carbon atoms. Specific examples include 2-mercaptoethanol, 4-mercapto-1-butanol, 6-mercapto-1-hexanol, mercaptomethyl ether, 2-mercaptoethyl ether, 3-mercaptopropyl ether, 4-mercaptobutyl ether, 5-mercaptopentyl ether, and 6-mercaptohexyl ether. Nitromethane is more preferably used.
[0047] Formula (2):
[0048] The amount of the compound that captures the by-product compound represented by formula (2) can be 0.1 to 100.0 mol %, preferably 1.0 to 50.0 mol %, and more preferably 2.0 to 40.0 mol %, based on the fluoride ion source that deprotects the hydroxyl-protecting group represented by formula (1).
[0049] The reaction between the nucleic acid oligomer represented by formula (3) and fluoride ions may be carried out by adding fluoride ions to the nucleic acid oligomer represented by formula (3), or conversely, by adding the nucleic acid oligomer represented by formula (3) to fluoride ions, or by adding both simultaneously. A method in which fluoride ions are added to the nucleic acid oligomer represented by formula (3) is preferred. The time required to add the entire amount of fluoride ions to the nucleic acid oligomer represented by formula (3) is preferably 5 minutes or more, more preferably 10 minutes or more, more preferably 15 minutes or more, more preferably 30 minutes or more, and even more preferably 1 hour or more. The addition is carried out dropwise onto the surface of or into the solution containing the nucleic acid oligomer represented by formula (3) over a period of preferably 5 minutes or more, more preferably 10 minutes or more, more preferably 15 minutes or more, more preferably 30 minutes or more, and even more preferably 1 hour or more. The radical reaction inhibitor is preferably present in the reaction system before the addition of fluoride ions.
[0050] The temperature of either or both of the solutions when fluoride ions are added to the nucleic acid oligomer represented by formula (3) may be 80° C. or lower, preferably both are 40° C. or lower, preferably both are 35° C. or lower, more preferably both are 30° C. or lower, more preferably both are 25° C. or lower, more preferably both are 20° C. or lower, more preferably both are 15° C. or lower, more preferably both are 10° C. or lower, and even more preferably both are 5° C. or lower. After the addition of fluoride ions to the nucleic acid oligomer represented by formula (3) is complete, the solution may be kept warm for 1 minute or longer, preferably 5 minutes or longer, more preferably 10 minutes or longer, more preferably 15 minutes or longer, more preferably 30 minutes or longer, and even more preferably 1 hour or longer. Furthermore, after the incubation, the temperature may be raised, and may be raised to 5°C or higher and 80°C or lower, preferably to 10°C or higher and 40°C or lower, preferably to 10°C or higher and 35°C or lower, preferably to 15°C or higher and 35°C or lower, more preferably to 20°C or higher and 35°C or lower, and even more preferably to 25°C or higher and 35°C or lower. After the temperature is raised, the time for the deprotection reaction varies depending on the type of deprotecting agent used and the reaction temperature, but is usually 1 hour to 100 hours, preferably 1 to 24 hours, more preferably 2 to 12 hours, and even more preferably 3 to 6 hours. Fluoride ions may be added at any timing.
[0051] Stirring of the reaction system during the deprotection reaction of the protecting group is not essential, but usually, the stirring power Pv is 0.0 to 0.5 kW / m 3 Stirring is carried out within the range of Pv 0.1 to 0.3 kW / m 3 It is preferable to stir the mixture.
[0052] The nucleic acid oligomer produced by the reaction can be separated and purified from the reaction mixture by conventional methods, and the purified nucleic acid oligomer can be isolated by using, for example, extraction, concentration, neutralization, filtration, centrifugation, recrystallization, silica gel column chromatography, thin layer chromatography, reverse-phase column chromatography, ion exchange column chromatography, gel filtration column chromatography, hydrophobic interaction chromatography, hydrophilic interaction liquid chromatography, affinity chromatography, precipitation (e.g., precipitation of the nucleic acid oligomer with ethanol, isopropanol, methanol, or polyethylene glycol), dialysis, or ultrafiltration. The isolated nucleic acid oligomer is usually obtained as a nucleic acid oligomer in which the hydroxyl group at its 5'-end is protected.
[0053] The reaction for obtaining a nucleic acid oligomer represented by the following formula (4) by deprotecting the protecting group represented by formula (1) from a nucleic acid oligomer represented by formula (3) is as follows (Scheme 1): Here, G in the formula 4 represents a protecting group for a hydrogen atom or a hydroxyl group; 9 represents an ammonium ion, an alkylammonium ion, an alkali metal ion, a hydrogen ion or a hydroxyalkylammonium ion; c are each independently the same or different and represent a nucleobase, R is each independently the same or different and represents a hydrogen atom, a fluorine atom, or an OQ group, Q is each independently the same or different and represents a tert-butyldimethylsilyl group, a methyl group, a 2-methoxyethyl group, a methylene group bonded to the carbon atom at the 4' position of ribose, an ethylene group bonded to the carbon atom at the 4' position of ribose, an ethylidene group bonded to the carbon atom at the 4' position of ribose, or a group represented by the following formula (1): (wherein, the bond marked with * represents a bond to the oxygen atom of the OQ group, and n represents an integer of 0 or greater), each Y is independently the same or different and represents an oxygen atom or a sulfur atom, m represents an integer of 2 or greater and 200, W and X are defined as either (a) or (b) below, (a) when W is a hydroxyl group, X has the same definition as the R group described above. (b) when X is a hydroxyl group, W represents an OV group, and V represents a tert-butyldimethylsilyl group or a group of the formula (1) described above, with the proviso that at least one group of the R, W, and X represents a hydroxyl group protected with a protecting group of the formula (1) described above. When m is an integer of 3 or greater, the nucleic acid oligomer represented by formula (3) is a nucleic acid oligomer in which a non-nucleotide linker may be incorporated in place of p nucleotides (where p is a positive integer satisfying the formula: m-1>p) between each of the 5'-terminal and 3'-terminal nucleotides.
[0054] In formula (3) or formula (4), when R represents an OQ group and R' represents an OQ' group, the structure of ribose is represented by the following formula (LNA-1), (LNA-2) or (LNA-3). (wherein Base represents a nucleic acid base)
[0055] Nucleosides (ribose and deoxyribose) contained in the nucleic acid oligomer used in this embodiment include, but are not limited to, DNA, RNA, 2'-O-MOE (2'-O-methoxyethyl), 2'-O-Me, 2'-F RNA, or the above-mentioned LNA.
[0056] The nucleic acid oligomer represented by formula (3) can be obtained, for example, by cleaving the nucleic acid oligomer produced by solid-phase synthesis represented by formula (5) from the solid support, as shown in Scheme 2 below.
[0057] The nucleic acid oligomer of formula (5) synthesized on a solid support will be described. aeach independently represents the same or different optionally protected nucleobase. 4 and Y are as defined in formula (3) above, 2 each independently represents the same or different protecting group for phosphate; 1 When represents OZ, W 1 represents an OV group, and V represents a tert-butyldimethylsilyl group or a group of the formula (1). 1 represents an R group, W 1 represents a group represented by OZ, and Z represents a group consisting of a solid phase carrier and a linking moiety connecting the solid phase carrier with the oxygen atom of the hydroxyl group at the 2'- or 3'-position of ribose at the 3'-end of the nucleic acid oligomer.
[0058] More specifically, Z represents a structure schematically shown in the following formula (6): -[Sp]-[Linker]-[Solid Support] (6) In formula (6), Sp represents a spacer. Examples of the spacer (Sp) include those having the structural formula shown in formula (7) below.
[0059]
[0060] Linker represents a structure that serves as a linker (junction structure). The structure of Linker may be, for example, a structure shown in the following formula (8-1), (8-2), (8-3), (8-4), (8-5), (8-6), (8-7), or (8-8). Solid support represents a structure that serves as a solid support. Examples of solid supports include inorganic porous supports and organic resin supports. Examples of inorganic porous supports include controlled pore glass (CPG) and zeolite. Examples of organic resin supports include supports made of polystyrene.
[0061]
[0062] (In the formula, each A may independently be a hydroxyl group, an alkoxy group, or an alkyl group. Examples of the alkoxy group include a methoxy group and an ethoxy group. Examples of the alkyl group include a methyl group, an ethyl group, an isopropyl group, and an n-propyl group. Si indicates that it is bonded to the oxygen of a hydroxyl group on the surface of the support.)
[0063] G 4 represents a protecting group for a hydrogen atom or a hydroxyl group, and when representing a protecting group, 1 represents the same protecting group as 4 is a hydrogen atom when deprotected, and the nucleotide compound in this state is also subjected to a series of steps in a nucleic acid extension reaction.
[0064] G 9 represents an ammonium ion, alkylammonium ion, alkali metal ion, hydrogen ion, hydroxyalkylammonium ion, or the like. Specific examples of the alkyl moiety of the alkylammonium ion include, for example, methyl, ethyl, n-propyl, isopropyl, n-butyl, dibutyl, isobutyl, tert-butyl, n-pentyl, isopentyl, and hexyl, and more specific examples include, for example, diethylammonium ion, triethylammonium ion, tetrabutylammonium ion, hexylammonium ion, and dibutylammonium ion. Examples of the alkali metal ion include, for example, sodium ion and lithium ion. Specific examples of the hydroxyalkyl moiety of the hydroxyalkylammonium ion include, for example, hydroxymethyl, hydroxyethyl, hydroxy-n-propyl, hydroxyisopropyl, hydroxy-n-butyl, and trishydroxymethyl, and more specific examples of the hydroxyalkylammonium ion include trishydroxymethylammonium ion.
[0065] The compound of formula (5) can be produced, for example, by the amidite method using an amidite compound of formula (A13) below. (wherein, R represents a hydrogen atom, a fluorine atom, or an OQ group; Q represents a tert-butyldimethylsilyl group, a methyl group, a 2-methoxyethyl group, a methylene group bonded to the 4' carbon atom, an ethylene group bonded to the 4' carbon atom, an ethylidene group bonded to the 4' carbon atom, or a protecting group represented by the formula (1); B a represents an optionally protected nucleobase; G 1 represents a protecting group for a hydroxyl group, 2 represents a protecting group for phosphate; 3 represents an alkyl group, or a ring structure formed by bonding together at their terminals.
[0066] B a Is B c or a nucleic acid base protected with a protecting group. a The nucleic acid base in is not particularly limited. Examples of the nucleic acid base include adenine, cytosine, guanine, uracil, thymine, 5-methylcytosine, pseudouracil, and 1-methylpseudouracil. The nucleic acid base may also be substituted with a substituent. Examples of such substituents include halogen atoms such as a fluoro group, a chloro group, a bromo group, or an iodo group, acyl groups such as an acetyl group, alkyl groups such as a methyl group or an ethyl group, arylalkyl groups such as a benzyl group, alkoxy groups such as a methoxy group, alkoxyalkyl groups such as a methoxyethyl group, cyanoalkyl groups such as a cyanoethyl group, hydroxy groups, hydroxyalkyl groups, acyloxymethyl groups, amino groups, monoalkylamino groups, dialkylamino groups, carboxy groups, cyano groups, and nitro groups, as well as combinations of two or more of these substituents.
[0067] When a nucleic acid base has an amino group outside the ring, the protecting group for the amino group is not particularly limited, and any protecting group known in nucleic acid chemistry can be used. Examples of such protecting groups include a benzoyl group, a 4-methoxybenzoyl group, an acetyl group, a propionyl group, a butyryl group, an isobutyryl group, a phenylacetyl group, a phenoxyacetyl group, a 4-tert-butylphenoxyacetyl group, a 4-isopropylphenoxyacetyl group, or a (dimethylamino)methylene group, as well as combinations of two or more of these protecting groups.
[0068] B a More specifically,
[0069] (In the above formula, R 4 represents a hydrogen atom, a methyl group, a phenoxyacetyl group, a 4-tert-butylphenoxyacetyl group, a 4-isopropylphenoxyacetyl group, a phenylacetyl group, an acetyl group, or a benzoyl group; R 5 represents a hydrogen atom, an acetyl group, an isobutyryl group, or a benzoyl group; R 6 represents a hydrogen atom, a phenoxyacetyl group, a 4-tert-butylphenoxyacetyl group, a 4-isopropylphenoxyacetyl group, a phenylacetyl group, an acetyl group, or an isobutyryl group; R 7 represents a 2-cyanoethyl group, R 8 represents a hydrogen atom, a methyl group, a benzoyl group, a 4-methoxybenzoyl group, or a 4-methylbenzoyl group; R 9 represents a dimethylaminomethylene group.
[0070] G 1There are no particular limitations on the protecting group, so long as it can function as a protecting group, and a wide range of known protecting groups used in amidite compounds can be used.
[0071] G 1 is preferably the following group:
[0072] (In the formula, R 1 , R 2 and R 3 are the same or different and represent hydrogen or an alkoxy group.
[0073] R 1 , R 2 and R 3 Preferably, one of the groups is hydrogen and the remaining two are the same or different (preferably the same) alkoxy groups, and a methoxy group is particularly preferred as the alkoxy group.
[0074] G 2 There are no particular limitations on the protecting group G as long as it can function as a protecting group, and a wide range of known protecting groups used in amidite compounds can be used. 2 Examples of the alkyl group include an alkyl group, an alkenyl group, an alkynyl group, a cycloalkyl group, a haloalkyl group, an aryl group, a heteroaryl group, an arylalkyl group, a cycloalkenyl group, a cycloalkylalkyl group, a cyclylalkyl group, a hydroxyalkyl group, an aminoalkyl group, an alkoxyalkyl group, a heterocyclylalkenyl group, a heterocyclylalkyl group, a heteroarylalkyl group, a silyl group, a silyloxyalkyl group, a mono- or dialkylsilyl group, or a trialkylsilyl group, or a monoalkylsilyloxyalkyl group, a dialkylsilyloxyalkyl group, or a trialkylsilyloxyalkyl group, and the like, which may be substituted with one or more electron-withdrawing groups.
[0075] G 2 is preferably an alkyl group substituted with an electron-withdrawing group. Examples of the electron-withdrawing group include a cyano group, a nitro group, an alkylsulfonyl group, a halogen atom, an arylsulfonyl group, a trihalomethyl group, and a trialkylamino group, and a cyano group is preferred.
[0076] G 2 Particularly preferred as are the following groups:
[0077] G 3 is two G 3 may be bonded to each other to form a cyclic structure. 3 Preferably, both of the groups are isopropyl groups.
[0078] The R 1 , R 2 , R 3 and G 2 The alkyl group in the definition may be either linear or branched, and is preferably an alkyl group having 1 to 12 carbon atoms, more preferably an alkyl group having 1 to 6 carbon atoms. Specific examples of the alkyl group include methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, n-pentyl, isopentyl, and hexyl. The alkyl group moiety constituting the alkoxy group in the above definition has the same definition as the alkyl group herein.
[0079] As used herein, the term "nucleobase" refers to a group having a natural or non-natural nucleobase backbone. The nucleobase also includes modified forms of the natural or non-natural nucleobase backbone. C More specifically, examples of the nucleic acid base represented by the formula (I) include the following structures:
[0080] (In the above formula, R 4’ represents a hydrogen atom or a methyl group; R 5’ represents a hydrogen atom or an acetyl group; R6’ represents a hydrogen atom, R 8’ represents a hydrogen atom or a methyl group.
[0081] Non-nucleotide linkers that can be introduced in place of the p nucleotides (where p is a positive integer satisfying the formula: m-1>p) between the 5'- and 3'-terminal nucleotides of the nucleic acid oligomers of formula (3) and formula (4) are described below. Examples of non-nucleotide linkers include linkers comprising an amino acid backbone (e.g., linkers comprising an amino acid backbone described in Japanese Patent No. 5,157,168 or Japanese Patent No. 5,554,881). Specific, non-limiting examples include linkers represented by the following formulas (A14-1), (A14-2), or (14-3) (e.g., described in Japanese Patent No. 5,555,346 or Japanese Patent No. 5,876,890). In addition to these linkers, examples include the linkers described in WO 2012 / 005368, WO 2018 / 182008, or WO 2019 / 074110.
[0082]
[0083] Nucleotides and amidites in which the R group in formula (3) and the R′ group in formula (4) are substituents other than a hydroxyl group can be produced from nucleosides synthesized by known methods described in Japanese Patent No. 3745226, WO 2001 / 053528, or JP 2014-221817 A and known methods cited therein, or can be produced using commercially available products in accordance with the methods described in the Examples below or by methods with appropriate modifications to these methods.
[0084] Cleavage of nucleic acid oligomer (hereinafter also referred to as oligonucleotide) from solid support The cleavage step was carried out on a nucleic acid oligomer of a desired chain length using concentrated aqueous ammonia as a cleavage agent.
[0085] In the phosphoramidite method, a nucleic acid extension reaction is carried out by repeatedly performing the deprotection step, the condensation step, and the oxidation step according to a generally known method (for example, the method described in the aforementioned Japanese Patent No. 5,157,168 or Japanese Patent No. 5,554,881).
[0086] (Nucleic acid extension reaction) In this specification, the term "nucleic acid extension reaction" refers to a reaction in which nucleotides are sequentially linked via phosphodiester bonds to extend an oligonucleotide. The nucleic acid extension reaction can be carried out according to the general procedure of the phosphoramidite method. The nucleic acid extension reaction may be carried out using an automatic nucleic acid synthesizer or the like that employs the phosphoramidite method.
[0087] The chain length of the nucleic acid oligomer may be, for example, 2 to 200 mer, 10 to 150 mer, or 15 to 110 mer.
[0088] The 5'-deprotection step is a step of deprotecting the protecting group of the 5' hydroxyl group at the end of the RNA strand supported on the solid phase support. Common protecting groups include the 4,4'-dimethoxytrityl group (DMTr group), the 4-monomethoxytrityl group, and the 4,4',4"-trimethoxytrityl group. Deprotection can be carried out using an acid. Examples of acids used for deprotection include trifluoroacetic acid, dichloroacetic acid, trifluoromethanesulfonic acid, trichloroacetic acid, methanesulfonic acid, hydrochloric acid, acetic acid, and p-toluenesulfonic acid.
[0089] The condensation step is a reaction in which a nucleoside phosphoramidite represented by formula (A13) is bonded to the 5' hydroxyl group at the end of the oligonucleotide chain deprotected in the deprotection step. The phosphoramidite used in nucleic acid elongation is an amidite compound represented by formula (A13) or (A12). Other usable phosphoramidites include 2'-OMe, 2'-F, 2'-O-tert-butyldimethylsilyl, 2'-O-methoxyethyl, 2'-H, 2'-fluoro-2'-deoxy-β-D-arabinofuranosyl, and the like. The nucleoside phosphoramidite used has its 5' hydroxyl group protected with a protecting group (e.g., a DMTr group). The condensation step can be carried out using an activator that activates the nucleoside phosphoramidite. Examples of the activator include 5-(benzylthio)-1H-tetrazole (BTT), 1H-tetrazole, 4,5-dicyanoimidazole (DCI), 5-(ethylthio)-1H-tetrazole (ETT), N-methylbenzimidazolium triflate (N-MeBIT), benzimidazolium triflate (BIT), N-phenylimidazolium triflate (N-PhIMT), imidazolium triflate (IMT), 5-nitrobenzimidazolium triflate (NBT), 1-hydroxybenzotriazole (HOBT), and 5-(bis-3,5-trifluoromethylphenyl)-1H-tetrazole.
[0090] After the condensation step, any unreacted 5' hydroxyl group may be capped, if desired, using a known capping solution such as an acetic anhydride-tetrahydrofuran solution or a phenoxyacetic anhydride / N-methylimidazole solution.
[0091] The oxidation step is a step of converting the phosphite group formed in the condensation step into a phosphate group or a thiophosphate group. This step is a reaction of converting trivalent phosphorus to pentavalent phosphorus using an oxidizing agent, and can be carried out by allowing the oxidizing agent to act on an oligonucleic acid derivative supported on a solid phase support. When converting a phosphite group into a phosphate group, the "oxidizing agent" can be, for example, iodine, a peracid such as tert-butyl hydroperoxide or hydrogen peroxide, (1S)-(+)-(10-camphorsulfonyl)-oxaziridine (CSO), or a mixture of two or more of these. The oxidizing agent can be diluted with an appropriate solvent to a concentration of 0.005 to 2 M before use. The solvent used in the reaction is not particularly limited as long as it is not involved in the reaction, but examples include pyridine, THF, water, acetonitrile, or any mixture of two or more of these. For example, iodine / water / pyridine / acetonitrile, iodine / water / pyridine, iodine / water / pyridine / acetonitrile / NMI, iodine / water / pyridine / THF, iodine / water / pyridine / THF / NMI, CSO / acetonitrile, iodine / pyridine-acetic acid, or peracid (tert-butyl hydroperoxide / methylene chloride) can be used.
[0092] When converting a phosphite triester group into a thiophosphate group, examples of the "oxidizing agent" that can be used include sulfur, 3H-1,2-benzodithiol-3-one-1,1-dioxide (Beaucage reagent), 3-amino-1,2,4-dithiazole-5-thione (ADTT), 5-phenyl-3H-1,2,4-dithiazol-3-one (POS), [(N,N-dimethylaminomethylidene)amino]-3H-1,2,4-dithiazoline-3-thione (DDTT), and phenylacetyl disulfide (PADS). The oxidizing agent can be diluted with an appropriate solvent to a concentration of 0.01 to 2 M before use. The solvent used in the reaction is not particularly limited as long as it is inert to the reaction, and examples include dichloromethane, acetonitrile, pyridine, and any mixtures thereof. The oxidation step may be carried out after the capping step, or conversely, the capping step may be carried out after the oxidation step, and this order is not limited.
[0093] In the step of deprotecting the phosphate protecting group, after the synthesis of a nucleic acid having a desired sequence is completed, an amine is reacted to deprotect the protecting group of the phosphate moiety. Examples of amines include diethylamine, which is described in Japanese Patent No. 4705716.
[0094] The protecting group for the 5' hydroxyl group of the nucleoside introduced at the end of elongation may be used for column purification using the 5' protecting group as a tag after cleavage from the solid phase support and deprotection of the protecting group as described below, and the protecting group for the 5' hydroxyl group may be deprotected after column purification.
[0095] Furthermore, the oligonucleotide chain is cleaved and recovered from the solid phase support using aqueous ammonia or amines, for example, as shown in Scheme 2. Examples of amines include methylamine, ethylamine, propylamine, isopropylamine, ethylenediamine, and diethylamine.
[0096] Nucleic acid oligomers that can be produced using the production method of this embodiment include, but are not limited to, nucleic acid oligomers in which the nucleosides contained therein are RNA, DNA, RNA having 2'-O-MOE, 2'-O-Me, or 2'-F, or LNA. Examples of various nucleosides include those described in Xiulong, Shen et al., Nucleic Acids Research, 2018, Vol. 46, No. 46, 1584-1600, or Daniel O'Reilly et al., Nucleic Acids Research, 2019, Vol. 47, No. 2, 546-558.
[0097] Typical examples of nucleic acid oligomers that can be used in the production method of this embodiment include, but are not limited to, the following examples in addition to those described in the Examples. In the following explanations of sequences, U represents uridine, C represents cytidine, A represents adenosine, and G represents guanosine.
[0098] Examples include nucleic acid oligomers having the following sequences (B) and (C), which are described in WO 2019 / 060442. Sequence (B): 5'-AUGGAAUmACUCUUGGUUmACdTdT-3' (antisense) (SEQ ID NO: 3) 21 mer Sequence (C): 5'-GUmAACmCmAAGAGUmAUmUmCmCmAUmdTdT-3' (sense) (SEQ ID NO: 4) 21 mer In sequences (B) and (C), Um represents 2'-O-methyluridine, Cm represents 2'-O-methylcytidine, and dT represents thymidine.
[0099] An example of such an oligonucleotide is the nucleic acid oligomer described in Daniel O'Reilly et al., Nucleic Acids Research, 2019, Vol. 47, No. 2, 546-558 (see page 553). A typical example is a nucleic acid oligomer having the following sequence (D): Sequence (D): 5'-AGAGCCAGCCUUCUUAUUGUUUUAGAGCUAUGCUGU-3' (SEQ ID NO: 5) 36mer
[0100] An example is the nucleic acid oligomer described in Japanese Patent No. 4,965,745. A typical example is a nucleic acid oligomer having the following sequence (E): Sequence (E): 5'-CCAUGAGAAGUAUGACAACAGCC-P-GGCUGUUGUCAUACUUCUCAUGGUU-3' 49mer. This sequence consists of CCAUGAGAAGUAUGACAACAGCC (SEQ ID NO: 6) and GGCUGUUGUCAUACUUCUCAUGGUU (SEQ ID NO: 7). In sequence (E), "P" is represented by the partial structure separated by a wavy line in the following formula (A5).
[0101] An example is a nucleic acid oligomer having the following sequence (F), which is described in Nucleic Acids Research, 2019, Vol. 47, No. 2: 547. Sequence (F): 5'-ACAGCAUAGCAAGUUAAAAUAAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCACCGAGUCGGUGCU-3' (SEQ ID NO: 8) 67mer
[0102] An example is a nucleic acid oligomer having the following sequence (G), which is described in JP 2015-523856, page 173: Sequence (G): 5'-GUUUUCCCUUUUCAAAGAAAUCUCCUGGGCACCUAUCUUCUUAGGUGCCCUCCCUUGUUUAAACCUGACCAGUUAACCGGCUGGUUAGGUUUUU-3' (SEQ ID NO: 9) 94mer
[0103] Examples of such oligomers include the nucleic acid oligomers described in JP 2017-537626. Typical examples include nucleic acid oligomers having the following sequences (H), (J), (K), and (L): Sequence (H): 5'-AGUCCUCAUCUCCCUCAAGCGUUUUAGAGCUAGUAAUAGCAAGUUAAAAUAAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCACCGAGUCGGUGCUUUU-3' (SEQ ID NO: 10) 100mer Sequence (J): 5'-GCAGAUGUAGUGUUUCCACAGUUUAAGAGCUAUGCUGGAAACAGCAUAGCAAGUUUAAAUAAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCACCGAGUCGGUGCUUUUUUU-3' (SEQ ID NO: 11) 113mer Sequence (K): 5'-dAdGdTdCdCdTdCdAdTdCdTdCdCdCdTdCdAdAdGdCGUUUAAGAGCUAUGCUGGUAACAGCAUAGCAAGUUUAAAUAAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCACCGAGUCGGUGCUUUUUUU-3' (SEQ ID NO: 12) 113 mer In sequence (K), dT represents thymidine, dC represents 2'-deoxycytidine, dA represents 2'-deoxyadenosine, and dG represents 2'-deoxyguanosine. Sequence (L): 5'-AmsGmsUmsCCUCAUCUCCCUCAAGCGUUUAAGAGCUAUGCUGGUAACAGCAUAGCAAGUUUAAAUAAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCACCGAGUCGGUGCUUUUmsUmsU-3' (SEQ ID NO: 13) 113 mer In sequence (L), Um represents 2'-O-methyluridine, Am represents 2'-O-methyladenosine, Gm represents 2'-O-methylguanosine, or phosphorothioate modification.
[0104] The present invention will be described in more detail below with reference to examples, but the present invention is not limited to these examples.
[0105] (Measurement Methods) The measurement methods used in the following tests are shown below.
[0106] (Measurement Method 1: Measurement Method of Oligonucleotide Purity) The purity of the crude oligonucleotide product after solid-phase synthesis was measured by HPLC. The crude product was separated into its components by HPLC (wavelength: 260 nm, column: ACQUITY UPLC Oligonucleotide BEH C18, 2.1 mm × 100 mm, 1.7 μm (manufactured by Waters)), and the purity of the oligonucleotide was calculated from the area value of the main product in the total area value of the obtained chromatogram.
[0107] The HPLC measurement conditions are shown in Table 1 below.
[0108] (Measurement Method 2: Measurement of Oligonucleotide Yield) OD of the crude product 260 The OD was measured. 260 represents the UV 260 nm absorbance per 10 mm path length in 1 mL of solution (pH = 7.5). It is generally known that 1 OD = 40 μg for RNA. 260 The yield was calculated based on the measured values. Furthermore, the yield per unit volume of the solid phase carrier was calculated. For Examples 1 to 21, the relative yield was determined with respect to the yield of Comparative Example 1. For Examples 22 to 33, the relative yield was determined with respect to the yield of Comparative Example 2.
[0109] (Solid-phase synthesis of oligonucleotides) Sequence (I): 5'-AGCAGAGUACACACAGCAUAUACC-P-GGUAUAUGCUGUGUGUACUCUGCUUC-PG-3' 53mer In the sequence (I), "A" is represented by the partial structure separated by a wavy line in the following formula (A1). "C" is represented by the partial structure separated by a wavy line in the following formula (A2). "G" is represented by the partial structure separated by a wavy line in the following formula (A3). U is represented by the partial structure separated by a wavy line in the following formula (A4). "P" is represented by the partial structure separated by a wavy line in the following formula (A5). "A" at the 5'-terminus is represented by the partial structure separated by a wavy line in the following formula (A6). Furthermore, "G" at the 3'-terminus is represented by the partial structure separated by a wavy line in the following formula (A7). However, the phosphate group in the structural formula may be a salt. In other words, sequence (I) consists of AGCAGAGUAC ACACAGCAUA UACC (SEQ ID NO: 1) and GGUAUAUGCU GUGUGUACUC UGCUUC (SEQ ID NO: 2) linked by the "P".
[0110]
[0111]
[0112]
[0113]
[0114]
[0115]
[0116]
[0117] Using controlled pore glass (CPG) as the solid phase support and an AKTA oligopilot plus 100 (GE Healthcare) as the nucleic acid synthesizer, the oligonucleotide consisting of the above sequence (I) was synthesized from the 3' to 5' end by phosphoramidite solid phase synthesis. The synthesis was carried out on a 77.89 μmol scale. Further, for the synthesis, uridine EMM amidite (A11) described in Example 2 of WO 2013 / 027843, cytidine EMM amidite (A9) described in Example 3, adenosine EMM amidite (A8) described in Example 4, guanosine EMM amidite (A10) described in Example 5, compound (A12) described in WO 2017 / 188042, and N described in Example 9 of Japanese Patent No. 5157168 were used. 6 -acetyl-5'-O-(4,4'-dimethoxytrityl)-2'-O-(2-cyanoethoxymethyl)adenosine 3'-O-(2-cyanoethyl N,N-diisopropylphosphoramidite (A15), N as described in Example 8 2 -acetyl-5'-O-(4,4'-dimethoxytrityl)-2'-O-(2-cyanoethoxymethyl)guanosine 3'-O-(2-cyanoethyl N,N-diisopropylphosphoramidite) (A17), N described in Example 5 4 The following compounds were used: 5'-acetyl-5'-O-(4,4'-dimethoxytrityl)-2'-O-(2-cyanoethoxymethyl)cytidine 3'-O-(2-cyanoethyl N,N-diisopropylphosphoramidite) (A16), and 5'-O-(4,4'-dimethoxytrityl)-2'-O-(2-cyanoethoxymethyl)uridine 3'-O-(2-cyanoethyl N,N-diisopropylphosphoramidite) (A18) described in Example 2; a dichloroacetic acid toluene solution was used as the deblocking solution; 5-(benzylthio)-1H-tetrazole was used as the condensing agent; an iodine solution was used as the oxidizing agent; and a phenoxyacetic anhydride solution and an N-methylimidazole solution were used as the capping solution. After nucleic acid elongation was completed, the cyanoethyl protecting groups on the phosphate moieties were selectively deprotected by applying a diethylamine solution to the nucleic acid on the carrier.
[0118]
[0119]
[0120]
[0121]
[0122]
[0123]
[0124]
[0125]
[0126]
[0127] Next, a specific example of the production of an oligonucleotide (nucleic acid oligomer) produced by the production method of this embodiment will be shown. The reaction was carried out under air (oxygen concentration 21%). Here, in the following examples, the oligonucleotide produced by the production method of this embodiment is an oligonucleotide having the sequence (I) shown in SEQ ID NOs: 1 and 2. Furthermore, the guanosine derivative described in the following examples and comparative examples refers to a compound represented by the following structural formula. The circle shown in the structural formula below is a schematic representation of CPG.
[0128]
[0129] (Example 1) Using 93.79 μmol of CPG carrying a guanosine derivative and the amidite shown in formula (A15), formula (A16), formula (A17), formula (A18), or formula (A12), solid-phase synthesis of sequence (I) was carried out using an AKTA oligopilot plus100. Then, 30.03 μmol of oligonucleotide-carrying CPG carrier was collected, and the oligonucleotide was liberated from the solid-phase carrier using 10.15 g of aqueous ammonia and 3.07 g of ethanol, after which the carrier was filtered off, and the filtrate containing the free oligonucleotide was concentrated to dryness. Next, the free oligonucleotide was dissolved in 13.24 g of dimethyl sulfoxide, and then 0.46 g of nitromethane and 2.99 g of acetonitrile were added to the solution, and 0.504 μmol of the solution was collected in a 15 mL Falcon tube. To this mixture, 0.73 mg of 2,6-di-tert-butyl-p-cresol (BHT) was added (0.1 mole of BHT per mole of protecting group) and dissolved. Then, 0.75 g of a 1 M dimethyl sulfoxide solution of tetra-n-butylammonium fluoride (TBAF) (27.1 moles of TBAF per mole of protecting group) that had been dehydrated using molecular sieves 4A was added. The mixture was stirred uniformly using a vortex mixer, and the 2'-cyanoethoxymethoxy (CEM) protecting group was deprotected by incubating at 30°C for 4 hours. The crude product was obtained by precipitation. The yield was 4.4 mg, and the purity was 52%. The purity of the resulting crude product was measured using the method described in Measurement Method 1 above, and the yield of the oligonucleotide was measured using the method described in Measurement Method 2 above.
[0130] (Example 2) Using 93.79 μmol of CPG carrying a guanosine derivative and the amidite shown in formula (A15), formula (A16), formula (A17), formula (A18), or formula (A12), solid-phase synthesis of sequence (I) was carried out using an AKTA oligopilot plus100. Then, 30.03 μmol of oligonucleotide-carrying CPG carrier was collected, and the oligonucleotide was liberated from the solid-phase carrier using 10.15 g of aqueous ammonia and 3.07 g of ethanol, after which the carrier was filtered off, and the filtrate containing the free oligonucleotide was concentrated to dryness. Next, the free oligonucleotide was dissolved in 13.24 g of dimethyl sulfoxide, and then 0.46 g of nitromethane and 2.99 g of acetonitrile were added to the solution, and 0.504 μmol of the solution was collected in a 15 mL Falcon tube. 2.85 mg of 2,6-di-tert-butyl-p-cresol (BHT) was added (0.5 moles of BHT per mole of protecting group) and dissolved. 0.75 g of a 1 M dimethyl sulfoxide solution of tetra-n-butylammonium fluoride (TBAF) (27.1 moles of TBAF per mole of protecting group) that had been dehydrated using molecular sieves 4A was then added. The mixture was stirred uniformly using a vortex mixer, and the 2'-cyanoethoxymethoxy (CEM) protecting group was deprotected by incubating at 30°C for 4 hours. The crude product was obtained by precipitation. The yield was 4.2 mg, and the purity was 53%. The purity of the resulting crude product was measured using the method described in Measurement Method 1 above, and the yield of the oligonucleotide was measured using the method described in Measurement Method 2 above.
[0131] (Example 3) Using 93.79 μmol of CPG carrying a guanosine derivative and the amidite shown in formula (A15), formula (A16), formula (A17), formula (A18), or formula (A12), solid-phase synthesis of sequence (I) was carried out using an AKTA oligopilot plus100. Then, 30.03 μmol of oligonucleotide-carrying CPG carrier was collected, and the oligonucleotide was liberated from the solid-phase carrier using 10.15 g of aqueous ammonia and 3.07 g of ethanol, after which the carrier was filtered off, and the filtrate containing the free oligonucleotide was concentrated to dryness. Next, the free oligonucleotide was dissolved in 13.24 g of dimethyl sulfoxide, and then 0.46 g of nitromethane and 2.99 g of acetonitrile were added to the solution, and 0.503 μmol of the solution was collected in a 15 mL Falcon tube. To this mixture, 5.83 mg of 2,6-di-tert-butyl-p-cresol (BHT) was added (1.0 mole of BHT per mole of protecting group) and dissolved. 0.75 g of a 1 M dimethyl sulfoxide solution of tetra-n-butylammonium fluoride (TBAF) (27.2 moles of TBAF per mole of protecting group) that had been dehydrated using molecular sieves 4A was then added. The mixture was stirred uniformly using a vortex mixer, and the 2'-cyanoethoxymethoxy (CEM) protecting group was deprotected by incubating at 30°C for 4 hours. The crude product was obtained by precipitation. The yield was 4.2 mg, and the purity was 53%. The purity of the resulting crude product was measured using the method described in Measurement Method 1 above, and the yield of the oligonucleotide was measured using the method described in Measurement Method 2 above.
[0132] (Example 4) Using 93.79 μmol of CPG carrying a guanosine derivative and the amidite shown in formula (A15), formula (A16), formula (A17), formula (A18), or formula (A12), solid-phase synthesis of sequence (I) was carried out using an AKTA oligopilot plus100. Then, 30.03 μmol of oligonucleotide-carrying CPG carrier was collected, and the oligonucleotide was liberated from the solid-phase carrier using 10.15 g of aqueous ammonia and 3.07 g of ethanol, after which the carrier was filtered off, and the filtrate containing the free oligonucleotide was concentrated to dryness. Next, the free oligonucleotide was dissolved in 13.24 g of dimethyl sulfoxide, and then 0.46 g of nitromethane and 2.99 g of acetonitrile were added to the solution, and 0.489 μmol of the solution was collected in a 15 mL Falcon tube. To this mixture, 11.56 mg of 2,6-di-tert-butyl-p-cresol (BHT) was added (2.1 moles of BHT per mole of protecting group) and dissolved. 0.75 g of a 1 M dimethyl sulfoxide solution of tetra-n-butylammonium fluoride (TBAF) (28.0 moles of TBAF per mole of protecting group) that had been dehydrated using molecular sieves 4A was then added. The mixture was stirred uniformly using a vortex mixer, and the 2'-cyanoethoxymethoxy (CEM) protecting group was deprotected by incubating at 30°C for 4 hours. The crude product was obtained by precipitation. The yield was 4.0 mg, and the purity was 53%. The purity of the resulting crude product was measured using the method described in Measurement Method 1 above, and the yield of the oligonucleotide was measured using the method described in Measurement Method 2 above.
[0133] (Example 5) Using CPG carrying 93.79 μmol of guanosine derivative and the amidite shown in formula (A15), formula (A16), formula (A17), formula (A18), or formula (A12), solid-phase synthesis of sequence (I) was carried out using AKTA Oligopilot Plus100. Then, 30.03 μmol of oligonucleotide-carrying CPG carrier was collected, and the oligonucleotide was liberated from the solid-phase carrier using 10.15 g of aqueous ammonia and 3.07 g of ethanol, after which the carrier was filtered off, and the filtrate containing the free oligonucleotide was concentrated to dryness. Next, the free oligonucleotide was dissolved in 13.24 g of dimethyl sulfoxide, and then 0.46 g of nitromethane and 2.99 g of acetonitrile were added to the solution, and 0.512 μmol of the solution was collected in a 15 mL Falcon tube. To this mixture, 17.81 mg of 2,6-di-tert-butyl-p-cresol (BHT) was added (3.0 moles of BHT per mole of protecting group) and dissolved. 0.79 g of a 1 M dimethyl sulfoxide solution of tetra-n-butylammonium fluoride (TBAF) (28.1 moles of TBAF per mole of protecting group) that had been dehydrated using molecular sieves 4A was then added. The mixture was stirred uniformly using a vortex mixer, and the 2'-cyanoethoxymethoxy (CEM) protecting group was deprotected by incubating at 30°C for 4 hours. The crude product was obtained by precipitation. The yield was 4.2 mg, and the purity was 52%. The purity of the resulting crude product was measured using the method described in Measurement Method 1 above, and the yield of the oligonucleotide was measured using the method described in Measurement Method 2 above.
[0134] (Example 6) Using 93.79 μmol of CPG carrying a guanosine derivative and the amidite shown in formula (A15), formula (A16), formula (A17), formula (A18), or formula (A12), solid-phase synthesis of sequence (I) was carried out using an AKTA oligopilot plus100. Then, 30.03 μmol of oligonucleotide-carrying CPG carrier was collected, and the oligonucleotide was liberated from the solid-phase carrier using 10.15 g of aqueous ammonia and 3.07 g of ethanol, after which the carrier was filtered off, and the filtrate containing the free oligonucleotide was concentrated to dryness. Next, the free oligonucleotide was dissolved in 13.24 g of dimethyl sulfoxide, and then 0.46 g of nitromethane and 2.99 g of acetonitrile were added to the solution, and 0.510 μmol of the solution was collected in a 15 mL Falcon tube. To this mixture, 23.11 mg of 2,6-di-tert-butyl-p-cresol (BHT) was added (4.0 moles of BHT per mole of protecting group) and dissolved. 0.76 g of a 1 M dimethyl sulfoxide solution of tetra-n-butylammonium fluoride (TBAF) (27.2 moles of TBAF per mole of protecting group) that had been dehydrated using molecular sieves 4A was then added. The mixture was stirred uniformly using a vortex mixer, and the 2'-cyanoethoxymethoxy (CEM) protecting group was deprotected by incubating at 30°C for 4 hours. The crude product was obtained by precipitation. The yield was 4.2 mg, and the purity was 52%. The purity of the resulting crude product was measured using the method described in Measurement Method 1 above, and the yield of the oligonucleotide was measured using the method described in Measurement Method 2 above.
[0135] (Example 7) Using 93.79 μmol of CPG carrying a guanosine derivative and the amidite shown in formula (A15), formula (A16), formula (A17), formula (A18), or formula (A12), solid-phase synthesis of sequence (I) was carried out using an AKTA oligopilot plus100. Then, 30.03 μmol of oligonucleotide-carrying CPG carrier was collected, and the oligonucleotide was liberated from the solid-phase carrier using 10.15 g of aqueous ammonia and 3.07 g of ethanol, after which the carrier was filtered off, and the filtrate containing the free oligonucleotide was concentrated to dryness. Next, the free oligonucleotide was dissolved in 13.24 g of dimethyl sulfoxide, and then 0.46 g of nitromethane and 2.99 g of acetonitrile were added to the solution, and 0.503 μmol of the solution was collected in a 15 mL Falcon tube. To this mixture, 7.20 mg of 4-sec-butyl-2,6-di-tert-butylphenol was added (the amount of 4-sec-butyl-2,6-di-tert-butylphenol was 1.0 mol per mol of protecting group) and dissolved. 0.75 g of a 1 M dimethyl sulfoxide solution of tetra-n-butylammonium fluoride (TBAF) (27.2 mol of TBAF per mol of protecting group) that had been dehydrated using molecular sieves 4A was then added, and the mixture was stirred uniformly using a vortex mixer. The mixture was then incubated at 30°C for 4 hours to deprotect the 2'-cyanoethoxymethoxy (CEM) protecting group. A crude product was obtained by precipitation. The yield was 4.2 mg, and the purity was 54%. The purity of the resulting crude product was measured using the method described in Measurement Method 1 above, and the yield of the oligonucleotide was measured using the method described in Measurement Method 2 above.
[0136] (Example 8) Using 93.79 μmol of CPG carrying a guanosine derivative and the amidite shown in formula (A15), formula (A16), formula (A17), formula (A18), or formula (A12), solid-phase synthesis of sequence (I) was carried out using an AKTA oligopilot plus100. Then, 30.03 μmol of oligonucleotide-carrying CPG carrier was collected, and the oligonucleotide was liberated from the solid-phase carrier using 10.15 g of aqueous ammonia and 3.07 g of ethanol, after which the carrier was filtered off, and the filtrate containing the free oligonucleotide was concentrated to dryness. Next, the free oligonucleotide was dissolved in 13.24 g of dimethyl sulfoxide, and then 0.46 g of nitromethane and 2.99 g of acetonitrile were added to the solution, and 0.485 μmol of the solution was collected in a 15 mL Falcon tube. To this mixture, 4.20 mg of 6-tert-butyl-2,4-xylenol was added (the amount of 6-tert-butyl-2,4-xylenol was 0.9 mol per mol of protecting group) and dissolved. Then, 0.76 g of a 1 M dimethyl sulfoxide solution of tetra-n-butylammonium fluoride (TBAF) (28.6 mol of TBAF per mol of protecting group) that had been dehydrated using molecular sieves 4A was added, and the mixture was stirred uniformly using a vortex mixer. The mixture was then incubated at 30°C for 4 hours to deprotect the 2'-cyanoethoxymethoxy (CEM) protecting group. A crude product was obtained by precipitation. The yield was 4.1 mg, and the purity was 56%. The purity of the resulting crude product was measured using the method described in Measurement Method 1 above, and the yield of the oligonucleotide was measured using the method described in Measurement Method 2 above.
[0137] (Example 9) Using 93.79 μmol of CPG carrying a guanosine derivative and the amidite shown in formula (A15), formula (A16), formula (A17), formula (A18), or formula (A12), solid-phase synthesis of sequence (I) was carried out using an AKTA oligopilot plus100. Then, 30.03 μmol of oligonucleotide-carrying CPG carrier was collected, and the oligonucleotide was liberated from the solid-phase carrier using 10.15 g of aqueous ammonia and 3.07 g of ethanol, after which the carrier was filtered off, and the filtrate containing the free oligonucleotide was concentrated to dryness. Next, the free oligonucleotide was dissolved in 13.24 g of dimethyl sulfoxide, and then 0.46 g of nitromethane and 2.99 g of acetonitrile were added to the solution, and 0.492 μmol of the solution was collected in a 15 mL Falcon tube. 5.30 mg of 4,6-di-tert-butyl-m-cresol was added (the amount of 4,6-di-tert-butyl-m-cresol was 0.9 mol per mol of protecting group) and dissolved. 0.77 g of a 1 M dimethyl sulfoxide solution of tetra-n-butylammonium fluoride (TBAF) (28.5 mol of TBAF per mol of protecting group) that had been dehydrated using molecular sieves 4A was then added. The mixture was stirred uniformly using a vortex mixer, and the mixture was then incubated at 30°C for 4 hours to deprotect the 2'-cyanoethoxymethoxy (CEM) protecting group. A crude product was obtained by precipitation. The yield was 4.4 mg, and the purity was 52%. The purity of the resulting crude product was measured using the method described in Measurement Method 1 above, and the yield of the oligonucleotide was measured using the method described in Measurement Method 2 above.
[0138] (Example 10) Using 93.79 μmol of CPG carrying a guanosine derivative and the amidite shown in formula (A15), formula (A16), formula (A17), formula (A18), or formula (A12), solid-phase synthesis of sequence (I) was carried out using an AKTA oligopilot plus100. Then, 30.03 μmol of oligonucleotide-carrying CPG carrier was collected, and the oligonucleotide was liberated from the solid-phase carrier using 10.15 g of aqueous ammonia and 3.07 g of ethanol, after which the carrier was filtered off, and the filtrate containing the free oligonucleotide was concentrated to dryness. Next, the free oligonucleotide was dissolved in 13.24 g of dimethyl sulfoxide, and then 0.46 g of nitromethane and 2.99 g of acetonitrile were added to the solution, and 0.506 μmol of the solution was collected in a 15 mL Falcon tube. 3.00 mg of 1,4-dihydroxybenzene was added (1.0 mole of 1,4-dihydroxybenzene per mole of protecting group) and dissolved. 0.75 g of a 1 M dimethyl sulfoxide solution of tetra-n-butylammonium fluoride (TBAF) (27.0 moles of TBAF per mole of protecting group) that had been dehydrated using molecular sieves 4A was then added. The mixture was stirred uniformly using a vortex mixer, and the mixture was then incubated at 30°C for 4 hours to deprotect the 2'-cyanoethoxymethoxy (CEM) protecting group. The crude product was obtained by precipitation. The yield was 4.3 mg, and the purity was 53%. The purity of the resulting crude product was measured using the method described in Measurement Method 1 above, and the yield of the oligonucleotide was measured using the method described in Measurement Method 2 above.
[0139] (Example 11) Using 93.79 μmol of CPG carrying a guanosine derivative and the amidite shown in formula (A15), formula (A16), formula (A17), formula (A18), or formula (A12), solid-phase synthesis of sequence (I) was carried out using an AKTA oligopilot plus100. Then, 30.03 μmol of oligonucleotide-carrying CPG carrier was collected, and the oligonucleotide was liberated from the solid-phase carrier using 10.15 g of aqueous ammonia and 3.07 g of ethanol, after which the carrier was filtered off, and the filtrate containing the free oligonucleotide was concentrated to dryness. Next, the free oligonucleotide was dissolved in 13.24 g of dimethyl sulfoxide, and then 0.46 g of nitromethane and 2.99 g of acetonitrile were added to the solution, and 0.493 μmol of the solution was collected in a 15 mL Falcon tube. To this mixture, 1.30 mg of bis(2,2,6,6-tetramethyl-4-piperidyl) sebacate was added (the amount of bis(2,2,6,6-tetramethyl-4-piperidyl) sebacate was 0.1 mole per mole of protecting group) and dissolved. 0.79 g of a 1 M dimethyl sulfoxide solution of tetra-n-butylammonium fluoride (TBAF) (the amount of TBAF was 29.2 moles per mole of protecting group) that had been dehydrated using molecular sieves 4A was then added, and the mixture was stirred uniformly using a vortex mixer. The mixture was then incubated at 30°C for 4 hours to deprotect the 2'-cyanoethoxymethoxy (CEM) protecting group. A crude product was obtained by precipitation. The yield was 4.3 mg, and the purity was 52%. The purity of the resulting crude product was measured using the method described in Measurement Method 1 above, and the yield of the oligonucleotide was measured using the method described in Measurement Method 2 above.
[0140] (Example 12) Using 93.79 μmol of CPG carrying a guanosine derivative and the amidite shown in formula (A15), formula (A16), formula (A17), formula (A18), or formula (A12), solid-phase synthesis of sequence (I) was carried out using an AKTA oligopilot plus100. Then, 30.03 μmol of oligonucleotide-carrying CPG carrier was collected, and the oligonucleotide was liberated from the solid-phase carrier using 10.15 g of aqueous ammonia and 3.07 g of ethanol, after which the carrier was filtered off, and the filtrate containing the free oligonucleotide was concentrated to dryness. Next, the free oligonucleotide was dissolved in 13.24 g of dimethyl sulfoxide, and then 0.46 g of nitromethane and 2.99 g of acetonitrile were added to the solution, and 0.492 μmol of the solution was collected in a 15 mL Falcon tube. To this mixture, 6.40 mg of bis(2,2,6,6-tetramethyl-4-piperidyl) sebacate was added (the amount of bis(2,2,6,6-tetramethyl-4-piperidyl) sebacate was 0.5 mol per mol of protecting group) and dissolved. 0.76 g of a 1 M dimethyl sulfoxide solution of tetra-n-butylammonium fluoride (TBAF) (the amount of TBAF was 28.2 mol per mol of protecting group) that had been dehydrated using molecular sieves 4A was then added, and the mixture was stirred uniformly using a vortex mixer. The mixture was then incubated at 30°C for 4 hours to deprotect the 2'-cyanoethoxymethoxy (CEM) protecting group. A crude product was obtained by precipitation. The yield was 4.3 mg, and the purity was 54%. The purity of the resulting crude product was measured using the method described in Measurement Method 1 above, and the yield of the oligonucleotide was measured using the method described in Measurement Method 2 above.
[0141] (Example 13) Using 93.79 μmol of CPG carrying a guanosine derivative and the amidite shown in formula (A15), formula (A16), formula (A17), formula (A18), or formula (A12), solid-phase synthesis of sequence (I) was carried out using an AKTA oligopilot plus100. Then, 30.03 μmol of oligonucleotide-carrying CPG carrier was collected, and the oligonucleotide was liberated from the solid-phase carrier using 10.15 g of aqueous ammonia and 3.07 g of ethanol, after which the carrier was filtered off, and the filtrate containing the free oligonucleotide was concentrated to dryness. Next, the free oligonucleotide was dissolved in 13.24 g of dimethyl sulfoxide, and then 0.46 g of nitromethane and 2.99 g of acetonitrile were added to the solution, and 0.511 μmol of the solution was collected in a 15 mL Falcon tube. 0.66 mg of 2,2,6,6-tetramethyl-4-piperidyl methacrylate was added (the amount of 2,2,6,6-tetramethyl-4-piperidyl methacrylate was 0.1 mole per mole of protecting group) and dissolved therein. 0.75 g of a 1 M dimethyl sulfoxide solution of tetra-n-butylammonium fluoride (TBAF) (26.8 moles of TBAF per mole of protecting group) that had been dehydrated using molecular sieves 4A was then added and stirred uniformly using a vortex mixer. The mixture was then incubated at 30°C for 4 hours to deprotect the 2'-cyanoethoxymethoxy (CEM) protecting group. A crude product was obtained by precipitation. The yield was 4.2 mg, and the purity was 52%. The purity of the resulting crude product was measured using the method described in Measurement Method 1 above, and the yield of the oligonucleotide was measured using the method described in Measurement Method 2 above.
[0142] (Example 14) Using 93.79 μmol of CPG carrying a guanosine derivative and the amidite shown in formula (A15), formula (A16), formula (A17), formula (A18), or formula (A12), solid-phase synthesis of sequence (I) was carried out using an AKTA oligopilot plus100. Then, 30.03 μmol of oligonucleotide-carrying CPG carrier was collected, and the oligonucleotide was liberated from the solid-phase carrier using 10.15 g of aqueous ammonia and 3.07 g of ethanol, after which the carrier was filtered off, and the filtrate containing the free oligonucleotide was concentrated to dryness. Next, the free oligonucleotide was dissolved in 13.24 g of dimethyl sulfoxide, and then 0.46 g of nitromethane and 2.99 g of acetonitrile were added to the solution, and 0.499 μmol of the solution was collected in a 15 mL Falcon tube. 2.80 mg of 2,2,6,6-tetramethyl-4-piperidyl methacrylate was added (the amount of 2,2,6,6-tetramethyl-4-piperidyl methacrylate was 0.5 moles per mole of protecting group) and dissolved therein. 0.79 g of a 1 M dimethyl sulfoxide solution of tetra-n-butylammonium fluoride (TBAF) (28.9 moles of TBAF per mole of protecting group) that had been dehydrated using molecular sieves 4A was then added and stirred uniformly using a vortex mixer. The mixture was then incubated at 30°C for 4 hours to deprotect the 2'-cyanoethoxymethoxy (CEM) protecting group. A crude product was obtained by precipitation. The yield was 4.0 mg, and the purity was 52%. The purity of the resulting crude product was measured using the method described in Measurement Method 1 above, and the yield of the oligonucleotide was measured using the method described in Measurement Method 2 above.
[0143] (Example 15) Using 93.79 μmol of CPG carrying a guanosine derivative and the amidite shown in formula (A15), formula (A16), formula (A17), formula (A18), or formula (A12), solid-phase synthesis of sequence (I) was carried out using an AKTA oligopilot plus100. Then, 30.03 μmol of oligonucleotide-carrying CPG carrier was collected, and the oligonucleotide was liberated from the solid-phase carrier using 10.15 g of aqueous ammonia and 3.07 g of ethanol, after which the carrier was filtered off, and the filtrate containing the free oligonucleotide was concentrated to dryness. Next, the free oligonucleotide was dissolved in 13.24 g of dimethyl sulfoxide, and then 0.46 g of nitromethane and 2.99 g of acetonitrile were added to the solution, and 0.495 μmol of the solution was collected in a 15 mL Falcon tube. To this mixture, 6.50 mg of 2,2,6,6-tetramethyl-4-piperidyl methacrylate was added (the amount of 2,2,6,6-tetramethyl-4-piperidyl methacrylate was 1.1 moles per mole of protecting group) and dissolved. 0.75 g of a 1 M dimethyl sulfoxide solution of tetra-n-butylammonium fluoride (TBAF) (27.6 moles of TBAF per mole of protecting group) that had been dehydrated using molecular sieves 4A was then added, and the mixture was stirred uniformly using a vortex mixer. The mixture was then incubated at 30°C for 4 hours to deprotect the 2'-cyanoethoxymethoxy (CEM) protecting group. A crude product was obtained by precipitation. The yield was 4.0 mg, and the purity was 52%. The purity of the resulting crude product was measured using the method described in Measurement Method 1 above, and the yield of the oligonucleotide was measured using the method described in Measurement Method 2 above.
[0144] (Example 16) Using 93.79 μmol of CPG carrying a guanosine derivative and the amidite shown in formula (A15), formula (A16), formula (A17), formula (A18), or formula (A12), solid-phase synthesis of sequence (I) was carried out using an AKTA oligopilot plus100. Then, 30.03 μmol of oligonucleotide-carrying CPG carrier was collected, and the oligonucleotide was liberated from the solid-phase carrier using 10.15 g of aqueous ammonia and 3.07 g of ethanol, after which the carrier was filtered off, and the filtrate containing the free oligonucleotide was concentrated to dryness. Next, the free oligonucleotide was dissolved in 13.24 g of dimethyl sulfoxide, and then 0.46 g of nitromethane and 2.99 g of acetonitrile were added to the solution, and 0.508 μmol of the solution was collected in a 15 mL Falcon tube. To this mixture, 4.9 mg of 2,2,6,6-tetramethylpiperidine 1-oxyl free radical was added (the amount of 2,2,6,6-tetramethylpiperidine 1-oxyl free radical was 1.2 moles per mole of protecting group) and dissolved. 0.83 g of a 1 M dimethyl sulfoxide solution of tetra-n-butylammonium fluoride (TBAF) (the amount of TBAF was 29.8 moles per mole of protecting group) that had been dehydrated using molecular sieves 4A was then added, and the mixture was stirred uniformly using a vortex mixer. The mixture was then incubated at 30°C for 4 hours to deprotect the 2'-cyanoethoxymethoxy (CEM) protecting group. A crude product was obtained by precipitation. The yield was 4.2 mg, and the purity was 55%. The purity of the resulting crude product was measured using the method described in Measurement Method 1 above, and the yield of the oligonucleotide was measured using the method described in Measurement Method 2 above.
[0145] (Example 17) Using 93.79 μmol of CPG carrying a guanosine derivative and the amidite shown in formula (A15), formula (A16), formula (A17), formula (A18), or formula (A12), solid-phase synthesis of sequence (I) was carried out using an AKTA oligopilot plus100. Then, 30.03 μmol of oligonucleotide-carrying CPG carrier was collected, and the oligonucleotide was liberated from the solid-phase carrier using 10.15 g of aqueous ammonia and 3.07 g of ethanol, after which the carrier was filtered off, and the filtrate containing the free oligonucleotide was concentrated to dryness. Next, the free oligonucleotide was dissolved in 13.24 g of dimethyl sulfoxide, and then 0.46 g of nitromethane and 2.99 g of acetonitrile were added to the solution, and 0.485 μmol of the solution was collected in a 15 mL Falcon tube. To this mixture, 14.30 mg of dioctadecyl sulfide was added (the amount of dioctadecyl sulfide was 1.1 moles per mole of protecting group), and 0.28 g of dimethyl sulfoxide was further added and dissolved. 0.78 g of a 1 M dimethyl sulfoxide solution of tetra-n-butylammonium fluoride (TBAF) (the amount of TBAF was 29.3 moles per mole of protecting group) that had been dehydrated using molecular sieves 4A was then added, and the mixture was stirred uniformly using a vortex mixer. The mixture was then incubated at 30°C for 4 hours to deprotect the 2'-cyanoethoxymethoxy (CEM) protecting group. A crude product was obtained by precipitation. The yield was 4.0 mg, and the purity was 55%. The purity of the resulting crude product was measured using the method described in Measurement Method 1 above, and the yield of the oligonucleotide was measured using the method described in Measurement Method 2 above.
[0146] (Example 18) Using 93.79 μmol of CPG carrying a guanosine derivative and the amidite shown in formula (A15), formula (A16), formula (A17), formula (A18), or formula (A12), solid-phase synthesis of sequence (I) was carried out using an AKTA oligopilot plus100. Then, 30.03 μmol of oligonucleotide-carrying CPG carrier was collected, and the oligonucleotide was liberated from the solid-phase carrier using 10.15 g of aqueous ammonia and 3.07 g of ethanol, after which the carrier was filtered off, and the filtrate containing the free oligonucleotide was concentrated to dryness. Next, the free oligonucleotide was dissolved in 13.24 g of dimethyl sulfoxide, and then 0.46 g of nitromethane and 2.99 g of acetonitrile were added to the solution, and 0.489 μmol of the solution was collected in a 15 mL Falcon tube. To this mixture, 5.00 mg of benzophenone was added (1.1 moles of benzophenone per mole of protecting group) and dissolved. 0.79 g of a 1 M dimethyl sulfoxide solution of tetra-n-butylammonium fluoride (TBAF) (29.5 moles of TBAF per mole of protecting group) that had been dehydrated using molecular sieves 4A was then added. The mixture was stirred uniformly using a vortex mixer, and the mixture was then incubated at 30°C for 4 hours to deprotect the 2'-cyanoethoxymethoxy (CEM) protecting group. A crude product was obtained by precipitation. The yield was 4.2 mg, and the purity was 55%. The purity of the resulting crude product was measured using the method described in Measurement Method 1 above, and the yield of the oligonucleotide was measured using the method described in Measurement Method 2 above.
[0147] (Example 19) Using 93.79 μmol of CPG carrying a guanosine derivative and the amidite shown in formula (A15), formula (A16), formula (A17), formula (A18), or formula (A12), solid-phase synthesis of sequence (I) was carried out using an AKTA oligopilot plus100. Then, 30.03 μmol of oligonucleotide-carrying CPG carrier was collected, and the oligonucleotide was liberated from the solid-phase carrier using 10.15 g of aqueous ammonia and 3.07 g of ethanol, after which the carrier was filtered off, and the filtrate containing the free oligonucleotide was concentrated to dryness. Next, the free oligonucleotide was dissolved in 13.24 g of dimethyl sulfoxide, and then 0.46 g of nitromethane and 2.99 g of acetonitrile were added to the solution, and 0.505 μmol of the solution was collected in a 15 mL Falcon tube. To this mixture, 4.10 mg of n-octanohydrazide was added (the amount of n-octanohydrazide was 1.0 mol per mol of protecting group) and dissolved. 0.79 g of a 1 M dimethyl sulfoxide solution of tetra-n-butylammonium fluoride (TBAF) (28.5 mol of TBAF per mol of protecting group) that had been dehydrated using molecular sieves 4A was then added. The mixture was stirred uniformly using a vortex mixer, and the mixture was then incubated at 30°C for 4 hours to deprotect the 2'-cyanoethoxymethoxy (CEM) protecting group. A crude product was obtained by precipitation. The yield was 4.3 mg, and the purity was 54%. The purity of the resulting crude product was measured using the method described in Measurement Method 1 above, and the yield of the oligonucleotide was measured using the method described in Measurement Method 2 above.
[0148] (Example 20) Using 93.79 μmol of CPG carrying a guanosine derivative and the amidite shown in formula (A15), formula (A16), formula (A17), formula (A18), or formula (A12), solid-phase synthesis of sequence (I) was carried out using AKTA Oligopilot Plus100. Then, 30.03 μmol of oligonucleotide-carrying CPG carrier was collected, and the oligonucleotide was liberated from the solid-phase carrier using 10.15 g of aqueous ammonia and 3.07 g of ethanol, after which the carrier was filtered off, and the filtrate containing the free oligonucleotide was concentrated to dryness. Next, the free oligonucleotide was dissolved in 13.24 g of dimethyl sulfoxide, and then 0.46 g of nitromethane and 2.99 g of acetonitrile were added to the solution, and 0.500 μmol of the solution was collected in a 15 mL Falcon tube. To this mixture, 3.90 mg of succinic dihydrazide was added (the amount of succinic dihydrazide was 1.0 mol per mol of protecting group) and dissolved. 0.81 g of a 1 M dimethyl sulfoxide solution of tetra-n-butylammonium fluoride (TBAF) (the amount of TBAF was 29.6 mol per mol of protecting group) that had been dehydrated using molecular sieves 4A was then added, and the mixture was stirred uniformly using a vortex mixer. The mixture was then incubated at 30°C for 4 hours to deprotect the 2'-cyanoethoxymethoxy (CEM) protecting group. A crude product was obtained by precipitation. The yield was 4.1 mg, and the purity was 52%. The purity of the resulting crude product was measured using the method described in Measurement Method 1 above, and the yield of the oligonucleotide was measured using the method described in Measurement Method 2 above.
[0149] (Example 21) Using CPG carrying 93.79 μmol of guanosine derivative and the amidite shown in formula (A15), formula (A16), formula (A17), formula (A18), or formula (A12), solid-phase synthesis of sequence (I) was carried out using AKTA Oligopilot Plus100. Then, 30.03 μmol of oligonucleotide-carrying CPG carrier was collected, and the oligonucleotide was liberated from the solid-phase carrier using 10.15 g of aqueous ammonia and 3.07 g of ethanol, after which the carrier was filtered off, and the filtrate containing the free oligonucleotide was concentrated to dryness. Next, the free oligonucleotide was dissolved in 13.24 g of dimethyl sulfoxide, and then 0.46 g of nitromethane and 2.99 g of acetonitrile were added to the solution, and 0.494 μmol of the solution was collected in a 15 mL Falcon tube. To this mixture, 6.00 mg of triphenylphosphine was added (0.9 moles of triphenylphosphine per mole of protecting group) and dissolved. 0.79 g of a 1 M dimethyl sulfoxide solution of tetra-n-butylammonium fluoride (TBAF) (29.2 moles of TBAF per mole of protecting group) that had been dehydrated using molecular sieves 4A was then added, and the mixture was stirred uniformly using a vortex mixer. The mixture was then incubated at 30°C for 4 hours to deprotect the 2'-cyanoethoxymethoxy (CEM) protecting group. A crude product was obtained by precipitation. The yield was 4.3 mg, and the purity was 54%. The purity of the resulting crude product was measured using the method described in Measurement Method 1 above, and the yield of the oligonucleotide was measured using the method described in Measurement Method 2 above.
[0150] (Comparative Example 1) Using CPG carrying 93.79 μmol of guanosine derivative and the amidite shown in formula (A15), formula (A16), formula (A17), formula (A18), or formula (A12), solid-phase synthesis of sequence (I) was carried out using AKTA Oligopilot Plus100. Then, 30.03 μmol of oligonucleotide-carrying CPG carrier was collected, and the oligonucleotide was liberated from the solid-phase carrier using 10.15 g of aqueous ammonia and 3.07 g of ethanol, after which the carrier was filtered off, and the filtrate containing the free oligonucleotide was concentrated to dryness. Then, the free oligonucleotide was dissolved in 13.24 g of dimethyl sulfoxide, and then 0.46 g of nitromethane and 2.99 g of acetonitrile were added to the solution, and 0.498 μmol of the solution was collected in a 15 mL Falcon tube. 0.78 g of a 1 M dimethyl sulfoxide solution of tetra-n-butylammonium fluoride (TBAF) (28.6 moles of TBAF per mole of protecting group) that had been dehydrated using molecular sieves 4A was added thereto, and the mixture was stirred uniformly using a vortex mixer. The mixture was then incubated at 30°C for 4 hours to deprotect the 2'-cyanoethoxymethoxy (CEM) protecting group. A crude product was obtained by precipitation. The yield was 4.1 mg, and the purity was 48%. The purity of the oligonucleotide from the obtained crude product was measured using the method described in Measurement Method 1 above, and the yield of the oligonucleotide was measured using the method described in Measurement Method 2 above.
[0151] (Example 22) Using CPG carrying 93.86 μmol of guanosine derivative and the amidite shown in formula (A8), formula (A9), formula (A10), formula (A11), or formula (A12), solid-phase synthesis of sequence (I) was carried out using AKTA Oligopilot Plus100. Then, 30.02 μmol of oligonucleotide-carrying CPG carrier was collected, and the oligonucleotide was liberated from the solid-phase carrier using 10.18 g of aqueous ammonia and 3.03 g of ethanol, after which the carrier was filtered off, and the filtrate containing the free oligonucleotide was concentrated to dryness. Next, the free oligonucleotide was dissolved in 13.24 g of dimethyl sulfoxide, and then 3.00 g of acetonitrile was added to the solution, and 0.504 μmol of the solution was collected in a 15 mL Falcon tube. To this mixture, 2.89 mg of nitromethane and 1.15 mg of 2,6-di-tert-butyl-p-cresol (BHT) were added (the amount of BHT was 0.2 moles per mole of protecting group) and dissolved. 0.78 g of a 1 M dimethyl sulfoxide solution of tetra-n-butylammonium fluoride (TBAF) (the amount of TBAF was 28.2 moles per mole of protecting group) that had been dehydrated using molecular sieves 4A was then added, and the mixture was stirred uniformly using a vortex mixer. The mixture was then incubated at 30°C for 4 hours to deprotect the 2'-EMM protecting group. The deprotection of the protecting group was carried out. A crude product was obtained by precipitation. The yield was 4.2 mg, and the purity was 53%. The purity of the resulting crude product was measured using the method described in Measurement Method 1 above, and the yield of the oligonucleotide was measured using the method described in Measurement Method 2 above.
[0152] (Example 23) Using CPG carrying 93.86 μmol of guanosine derivative and the amidite shown in formula (A8), formula (A9), formula (A10), formula (A11), or formula (A12), solid-phase synthesis of sequence (I) was carried out using AKTA Oligopilot Plus100. Then, 30.02 μmol of oligonucleotide-carrying CPG carrier was collected, and the oligonucleotide was liberated from the solid-phase carrier using 10.18 g of aqueous ammonia and 3.03 g of ethanol, after which the carrier was filtered off, and the filtrate containing the free oligonucleotide was concentrated to dryness. Next, the free oligonucleotide was dissolved in 13.24 g of dimethyl sulfoxide, and then 0.513 μmol of the solution was collected from the solution to which 3.00 g of acetonitrile was added in a 15 mL Falcon tube. To this mixture, 2.89 mg of nitromethane and 5.87 mg of 2,6-di-tert-butyl-p-cresol (BHT) were added (1.0 mole of BHT per mole of protecting group) and dissolved. 0.78 g of a 1 M dimethyl sulfoxide solution of tetra-n-butylammonium fluoride (TBAF) (27.7 moles of TBAF per mole of protecting group) that had been dehydrated using molecular sieves 4A was then added. The mixture was stirred uniformly using a vortex mixer, and the 2'-EMM protecting group was deprotected by incubating at 30°C for 4 hours. The deprotection of the protecting group was carried out. A crude product was obtained by precipitation. The yield was 4.0 mg, and the purity was 53%. The purity of the resulting crude product was measured using the method described in Measurement Method 1 above, and the yield of the oligonucleotide was measured using the method described in Measurement Method 2 above.
[0153] (Example 24) Using CPG carrying 93.86 μmol of guanosine derivative and the amidite shown in formula (A8), formula (A9), formula (A10), formula (A11), or formula (A12), solid-phase synthesis of sequence (I) was carried out using AKTA Oligopilot Plus100. Then, 30.02 μmol of oligonucleotide-carrying CPG carrier was collected, and the oligonucleotide was liberated from the solid-phase carrier using 10.18 g of aqueous ammonia and 3.03 g of ethanol, after which the carrier was filtered off, and the filtrate containing the free oligonucleotide was concentrated to dryness. Next, the free oligonucleotide was dissolved in 13.24 g of dimethyl sulfoxide, and then 0.511 μmol of the solution was collected from the solution to which 3.00 g of acetonitrile was added in a 15 mL Falcon tube. To this mixture, 2.89 mg of nitromethane and 23.20 mg of 2,6-di-tert-butyl-p-cresol (BHT) were added (4.0 moles of BHT per mole of protecting group) and dissolved. 0.78 g of a 1 M dimethyl sulfoxide solution of tetra-n-butylammonium fluoride (TBAF) (27.8 moles of TBAF per mole of protecting group) that had been dehydrated using molecular sieves 4A was then added. The mixture was stirred uniformly using a vortex mixer, and the 2'-EMM protecting group was deprotected by incubating at 30°C for 4 hours. The deprotection of the protecting group was carried out. A crude product was obtained by precipitation. The yield was 4.3 mg, and the purity was 55%. The purity of the resulting crude product was measured using the method described in Measurement Method 1 above, and the yield of the oligonucleotide was measured using the method described in Measurement Method 2 above.
[0154] (Example 25) Using 93.86 μmol of CPG carrying a guanosine derivative and the amidite shown in formula (A8), formula (A9), formula (A10), formula (A11), or formula (A12), solid-phase synthesis of sequence (I) was carried out using AKTA Oligopilot Plus100. Then, 30.02 μmol of oligonucleotide-carrying CPG carrier was collected, and the oligonucleotide was liberated from the solid-phase carrier using 10.18 g of aqueous ammonia and 3.03 g of ethanol, after which the carrier was filtered, and the filtrate containing the free oligonucleotide was concentrated to dryness. Then, the free oligonucleotide was dissolved in 13.24 g of dimethyl sulfoxide, and then 0.514 μmol of the solution was collected from the solution to which 3.00 g of acetonitrile was added in a 15 mL Falcon tube. To this mixture, 2.89 mg of nitromethane and 34.10 mg of 2,6-di-tert-butyl-p-cresol (BHT) were added (5.8 moles of BHT per mole of protecting group) and dissolved. 0.82 g of a 1 M dimethyl sulfoxide solution of tetra-n-butylammonium fluoride (TBAF) (29.1 moles of TBAF per mole of protecting group) that had been dehydrated using molecular sieves 4A was then added. The mixture was stirred uniformly using a vortex mixer, and the 2'-EMM protecting group was deprotected by incubating at 30°C for 4 hours. The deprotection of the protecting group was carried out. A crude product was obtained by precipitation. The yield was 4.4 mg, and the purity was 55%. The purity of the resulting crude product was measured using the method described in Measurement Method 1 above, and the yield of the oligonucleotide was measured using the method described in Measurement Method 2 above.
[0155] (Example 26) Using CPG carrying 93.86 μmol of guanosine derivative and the amidite shown in formula (A8), formula (A9), formula (A10), formula (A11), or formula (A12), solid-phase synthesis of sequence (I) was carried out using AKTA Oligopilot Plus100. Then, 30.02 μmol of oligonucleotide-carrying CPG carrier was collected, and the oligonucleotide was liberated from the solid-phase carrier using 10.18 g of aqueous ammonia and 3.03 g of ethanol, after which the carrier was filtered, and the filtrate containing the free oligonucleotide was concentrated to dryness. Next, the free oligonucleotide was dissolved in 13.24 g of dimethyl sulfoxide, and then 0.508 μmol of the solution was collected from the solution to which 3.00 g of acetonitrile was added in a 15 mL Falcon tube. To this mixture, 2.89 mg of nitromethane and 47.10 mg of 2,6-di-tert-butyl-p-cresol (BHT) were added (8.1 moles of BHT per mole of protecting group) and dissolved. 0.76 g of a 1 M dimethyl sulfoxide solution of tetra-n-butylammonium fluoride (TBAF) (27.3 moles of TBAF per mole of protecting group) that had been dehydrated using molecular sieves 4A was then added. The mixture was stirred uniformly using a vortex mixer, and the 2'-EMM protecting group was deprotected by incubating at 30°C for 4 hours. The deprotection of the protecting group was carried out. A crude product was obtained by precipitation. The yield was 4.3 mg, and the purity was 54%. The purity of the resulting crude product was measured using the method described in Measurement Method 1 above, and the yield of the oligonucleotide was measured using the method described in Measurement Method 2 above.
[0156] (Example 27) Using CPG carrying 93.86 μmol of guanosine derivative and the amidite shown in formula (A8), formula (A9), formula (A10), formula (A11), or formula (A12), solid-phase synthesis of sequence (I) was carried out using AKTA Oligopilot Plus100. Then, 30.02 μmol of oligonucleotide-carrying CPG carrier was collected, and the oligonucleotide was liberated from the solid-phase carrier using 10.18 g of aqueous ammonia and 3.03 g of ethanol, after which the carrier was filtered off, and the filtrate containing the free oligonucleotide was concentrated to dryness. Next, the free oligonucleotide was dissolved in 13.24 g of dimethyl sulfoxide, and then 0.513 μmol of the solution was collected from the solution to which 3.00 g of acetonitrile was added in a 15 mL Falcon tube. To this mixture, 2.89 mg of nitromethane and 6.00 mg of 6-tert-butyl-2,4-xylenol were added (the amount of 6-tert-butyl-2,4-xylenol was 1.3 moles per mole of protecting group) and dissolved. 0.78 g of a 1 M dimethyl sulfoxide solution of tetra-n-butylammonium fluoride (TBAF) (the amount of TBAF was 27.8 moles per mole of protecting group) that had been dehydrated using molecular sieves 4A was then added, and the mixture was stirred uniformly using a vortex mixer. The mixture was then incubated at 30°C for 4 hours to deprotect the 2'-EMM protecting group. The deprotection of the protecting group was carried out. A crude product was obtained by precipitation. The yield was 4.5 mg, and the purity was 54%. The purity of the resulting crude product was measured using the method described in Measurement Method 1 above, and the yield of the oligonucleotide was measured using the method described in Measurement Method 2 above.
[0157] (Example 28) Using CPG carrying 93.86 μmol of guanosine derivative and the amidite shown in formula (A8), formula (A9), formula (A10), formula (A11), or formula (A12), solid-phase synthesis of sequence (I) was carried out using AKTA Oligopilot Plus100. Then, 30.02 μmol of oligonucleotide-carrying CPG carrier was collected, and the oligonucleotide was liberated from the solid-phase carrier using 10.18 g of aqueous ammonia and 3.03 g of ethanol, after which the carrier was filtered off, and the filtrate containing the free oligonucleotide was concentrated to dryness. Next, the free oligonucleotide was dissolved in 13.24 g of dimethyl sulfoxide, and then 0.520 μmol of the solution was collected from the solution to which 3.00 g of acetonitrile was added in a 15 mL Falcon tube. To this mixture, 2.89 mg of nitromethane and 5.10 mg of 4,6-di-tert-butyl-m-cresol were added (the amount of 4,6-di-tert-butyl-m-cresol was 0.9 mol per mol of protecting group) and dissolved. 0.78 g of a 1 M dimethyl sulfoxide solution of tetra-n-butylammonium fluoride (TBAF) (27.3 mol of TBAF per mol of protecting group) that had been dehydrated using molecular sieves 4A was then added, and the mixture was stirred uniformly using a vortex mixer. The mixture was then incubated at 30°C for 4 hours to deprotect the 2'-EMM protecting group. The deprotection of the protecting group was carried out. A crude product was obtained by precipitation. The yield was 4.3 mg, and the purity was 53%. The purity of the resulting crude product was measured using the method described in Measurement Method 1 above, and the yield of the oligonucleotide was measured using the method described in Measurement Method 2 above.
[0158] (Example 29) Using CPG carrying 93.86 μmol of guanosine derivative and the amidite shown in formula (A8), formula (A9), formula (A10), formula (A11), or formula (A12), solid-phase synthesis of sequence (I) was carried out using AKTA Oligopilot Plus100. Then, 30.02 μmol of oligonucleotide-carrying CPG carrier was collected, and the oligonucleotide was liberated from the solid-phase carrier using 10.18 g of aqueous ammonia and 3.03 g of ethanol, after which the carrier was filtered off, and the filtrate containing the free oligonucleotide was concentrated to dryness. Next, the free oligonucleotide was dissolved in 13.24 g of dimethyl sulfoxide, and then 0.504 μmol of the solution was collected from the solution to which 3.00 g of acetonitrile was added in a 15 mL Falcon tube. To this mixture, 2.89 mg of nitromethane and 0.70 mg of 2,2,6,6-tetramethyl-4-piperidyl methacrylate were added (the amount of 2,2,6,6-tetramethyl-4-piperidyl methacrylate was 0.1 mole per mole of protecting group) and dissolved. 0.78 g of a 1 M dimethyl sulfoxide solution of tetra-n-butylammonium fluoride (TBAF) (the amount of TBAF was 28.2 moles per mole of protecting group) that had been dehydrated using molecular sieves 4A was then added, and the mixture was stirred uniformly using a vortex mixer. The mixture was then incubated at 30°C for 4 hours to deprotect the 2'-EMM protecting group. The deprotection of the protecting group was carried out. A crude product was obtained by precipitation. The yield was 4.2 mg, and the purity was 50%. The purity of the resulting crude product was measured using the method described in Measurement Method 1 above, and the yield of the oligonucleotide was measured using the method described in Measurement Method 2 above.
[0159] (Example 30) Using 93.86 μmol of CPG carrying a guanosine derivative and the amidite shown in formula (A8), formula (A9), formula (A10), formula (A11), or formula (A12), solid-phase synthesis of sequence (I) was carried out using AKTA Oligopilot Plus100. Then, 30.02 μmol of oligonucleotide-carrying CPG carrier was collected, and the oligonucleotide was liberated from the solid-phase carrier using 10.18 g of aqueous ammonia and 3.03 g of ethanol, after which the carrier was filtered off, and the filtrate containing the free oligonucleotide was concentrated to dryness. Next, the free oligonucleotide was dissolved in 13.24 g of dimethyl sulfoxide, and then 0.511 μmol of the solution was collected from the solution to which 3.00 g of acetonitrile was added in a 15 mL Falcon tube. To this mixture, 2.89 mg of nitromethane and 4.50 mg of 2,2,6,6-tetramethylpiperidine 1-oxyl free radical were added (the amount of 2,2,6,6-tetramethylpiperidine 1-oxyl free radical was 1.1 mol per mol of protecting group), and dissolved. 0.78 g of a 1 M dimethyl sulfoxide solution of tetra-n-butylammonium fluoride (TBAF) (the amount of TBAF was 27.8 mol per mol of protecting group) that had been dehydrated using molecular sieves 4A was then added, and the mixture was stirred uniformly using a vortex mixer. The 2'-EMM protecting group was then deprotected by incubating the mixture at 30°C for 4 hours. The deprotection of the protecting group was carried out. A crude product was obtained by precipitation. The yield was 4.0 mg, and the purity was 52%. The purity of the resulting crude product was measured using the method described in Measurement Method 1 above, and the yield of the oligonucleotide was measured using the method described in Measurement Method 2 above.
[0160] (Example 31) Using CPG carrying 93.86 μmol of guanosine derivative and the amidite shown in formula (A8), formula (A9), formula (A10), formula (A11), or formula (A12), solid-phase synthesis of sequence (I) was carried out using AKTA Oligopilot Plus100. Then, 30.02 μmol of oligonucleotide-carrying CPG carrier was collected, and the oligonucleotide was liberated from the solid-phase carrier using 10.18 g of aqueous ammonia and 3.03 g of ethanol, after which the carrier was filtered off, and the filtrate containing the free oligonucleotide was concentrated to dryness. Next, the free oligonucleotide was dissolved in 13.24 g of dimethyl sulfoxide, and then 0.503 μmol of the solution was collected from the solution to which 3.00 g of acetonitrile was added in a 15 mL Falcon tube. To this mixture, 2.89 mg of nitromethane and 14.00 mg of dioctadecyl sulfide were added (the amount of dioctadecyl sulfide was 1.0 mol per mol of protecting group), and 0.28 g of dimethyl sulfoxide was added and dissolved. 0.81 g of a 1 M dimethyl sulfoxide solution of tetra-n-butylammonium fluoride (TBAF) (the amount of TBAF was 29.4 mol per mol of protecting group) that had been dehydrated using molecular sieves 4A was then added, and the mixture was stirred uniformly using a vortex mixer. The mixture was then incubated at 30°C for 4 hours to deprotect the 2'-EMM protecting group. The deprotection of the protecting group was carried out. A crude product was obtained by precipitation. The yield was 4.0 mg, and the purity was 54%. The purity of the resulting crude product was measured using the method described in Measurement Method 1 above, and the yield of the oligonucleotide was measured using the method described in Measurement Method 2 above.
[0161] (Example 32) Using 93.86 μmol of CPG carrying a guanosine derivative and the amidite shown in formula (A8), formula (A9), formula (A10), formula (A11), or formula (A12), solid-phase synthesis of sequence (I) was carried out using AKTA Oligopilot Plus100. Then, 30.02 μmol of oligonucleotide-carrying CPG carrier was collected, and the oligonucleotide was liberated from the solid-phase carrier using 10.18 g of aqueous ammonia and 3.03 g of ethanol, after which the carrier was filtered off, and the filtrate containing the free oligonucleotide was concentrated to dryness. Next, the free oligonucleotide was dissolved in 13.24 g of dimethyl sulfoxide, and then 0.521 μmol of the solution was collected from the solution to which 3.00 g of acetonitrile was added in a 15 mL Falcon tube. To this mixture, 2.89 mg of nitromethane and 4.80 mg of benzophenone were added (1.0 mole of benzophenone per mole of protecting group) and dissolved. 0.83 g of a 1 M dimethyl sulfoxide solution of tetra-n-butylammonium fluoride (TBAF) (29.0 moles of TBAF per mole of protecting group) that had been dehydrated using molecular sieves 4A was then added. The mixture was stirred uniformly using a vortex mixer, and the mixture was then incubated at 30°C for 4 hours to deprotect the 2'-EMM protecting group. The deprotection of the protecting group was carried out. A crude product was obtained by precipitation. The yield was 4.0 mg, and the purity was 53%. The purity of the resulting crude product was measured using the method described in Measurement Method 1 above, and the yield of the oligonucleotide was measured using the method described in Measurement Method 2 above.
[0162] (Example 33) Using CPG carrying 93.86 μmol of guanosine derivative and the amidite shown in formula (A8), formula (A9), formula (A10), formula (A11), or formula (A12), solid-phase synthesis of sequence (I) was carried out using AKTA Oligopilot Plus100. Then, 30.02 μmol of oligonucleotide-carrying CPG carrier was collected, and the oligonucleotide was liberated from the solid-phase carrier using 10.18 g of aqueous ammonia and 3.03 g of ethanol, after which the carrier was filtered off, and the filtrate containing the free oligonucleotide was concentrated to dryness. Next, the free oligonucleotide was dissolved in 13.24 g of dimethyl sulfoxide, and then 0.491 μmol of the solution was collected from the solution to which 3.00 g of acetonitrile was added in a 15 mL Falcon tube. To this mixture, 2.89 mg of nitromethane and 6.40 mg of triphenylphosphine were added (the amount of triphenylphosphine was 1.0 mol per mol of protecting group) and dissolved. 0.79 g of a 1 M dimethyl sulfoxide solution of tetra-n-butylammonium fluoride (TBAF) (the amount of TBAF was 29.4 mol per mol of protecting group) that had been dehydrated using molecular sieves 4A was then added, and the mixture was stirred uniformly using a vortex mixer. The mixture was then incubated at 30°C for 4 hours to deprotect the 2'-EMM protecting group. The deprotection of the protecting group was carried out. A crude product was obtained by precipitation. The yield was 4.0 mg, and the purity was 53%. The purity of the resulting crude product was measured using the method described in Measurement Method 1 above, and the yield of the oligonucleotide was measured using the method described in Measurement Method 2 above.
[0163] (Comparative Example 2) Using CPG carrying 93.86 μmol of guanosine derivative and the amidite shown in formula (A8), formula (A9), formula (A10), formula (A11), or formula (A12), solid-phase synthesis of sequence (I) was carried out using AKTA Oligopilot Plus100. Then, 30.02 μmol of oligonucleotide-carrying CPG carrier was collected, and the oligonucleotide was liberated from the solid-phase carrier using 10.18 g of aqueous ammonia and 3.03 g of ethanol, and then the carrier was filtered off, and the filtrate containing the free oligonucleotide was concentrated to dryness. Next, the free oligonucleotide was dissolved in 13.24 g of dimethyl sulfoxide, and then 0.510 μmol of the solution was collected from the solution to which 3.00 g of acetonitrile was added in a 15 mL Falcon tube. To this mixture, 2.89 mg of nitromethane was added, followed by the addition of 1.56 g of a 1 M dimethyl sulfoxide solution of tetra-n-butylammonium fluoride (TBAF) (55.8 moles of TBAF per mole of protecting group) that had been dehydrated using molecular sieves 4A. The mixture was stirred uniformly using a vortex mixer, and the 2'-EMM protecting group was deprotected by incubating the mixture at 30°C for 4 hours. The protecting group was deprotected. A crude product was obtained by precipitation. The yield was 4.1 mg, and the purity was 49%. The purity of the resulting crude product was measured using the method described in Measurement Method 1 above, and the yield of the oligonucleotide was measured using the method described in Measurement Method 2 above.
[0164] (Reference Example 1) Using the CPG carrying 93.86 μmol of guanosine derivative and the amidite shown in formula (A8), formula (A9), formula (A10), formula (A11) or formula (A12), the solid-phase synthesis of sequence (I) was carried out by AKTA oligopilot plus100. Then, the CPG carrier carrying 30.02 μmol of oligonucleotide was collected, and the oligonucleotide was liberated from the solid-phase carrier using 10.18 g of aqueous ammonia and 3.03 g of ethanol, and then the carrier was filtered off, and the filtrate containing the free oligonucleotide was concentrated to dryness. Then, the free oligonucleotide was dissolved in 13.24 g of dimethyl sulfoxide, and then 0.497 μmol of the solution was collected from the solution added with 3.00 g of acetonitrile into a Falcon tube with a capacity of 15 mL. To this mixture, 2.89 mg of nitromethane was added, followed by 0.82 g of a 1 M dimethyl sulfoxide solution of tetra-n-butylammonium fluoride (TBAF) (30.1 moles of TBAF per mole of protecting group) that had been dehydrated using molecular sieves 4A. The mixture was stirred uniformly using a vortex mixer, and then the mixture was incubated at 30°C for 4 hours to deprotect the 2'-EMM protecting group. The deprotection of the protecting group was carried out. The crude product was obtained by precipitation. The yield was 4.2 mg, with a purity of 49%. Furthermore, 4.7 mL of an aqueous solution containing the entire crude product obtained was purified by affinity chromatography. Specifically, the entire volume of the nucleic acid solution was applied to a commercially available affinity column (SkillPak Toyopearl AF-Chelate-650M, 1 mL, Tosoh Corporation) using Cytiva's AKTA pure 150. Water was used as the mobile phase, and 20 mL of the solution was pumped at a flow rate of 0.6 mL / min. The UV (260 nm) of the eluate was monitored, and the entire volume of the portion where nucleic acid elution was observed was collected and concentrated by membrane filtration to obtain purified nucleic acid.
[0165] The measurement results are shown in Tables 2 to 4. In the tables below, the amount of radical reaction inhibitor used means the amount used relative to the value obtained by multiplying 1 mol of the compound supported on the solid phase carrier by the number of times that R in formula (3) is a group represented by formula (1).
[0166]
[0167]
[0168]
[0169] As shown in Tables 2 to 4 above, by carrying out the deprotection reaction of the protecting group of the ribose hydroxyl group contained in the oligonucleotide described in the specification in the presence of a radical reaction inhibitor, the deprotection reaction proceeded more efficiently than when carried out in the absence of a radical reaction inhibitor, and as a result, deprotected oligonucleotides with high purity could be obtained.
[0170] According to the present invention, nucleic acid oligomers can be produced efficiently.
[0171] SEQ ID NOs: 1 to 13 in the sequence listing represent the base sequences of the oligonucleotides produced according to the production method of the present invention.
Claims
1. In the presence of a radical reaction inhibitor, the following formula (3): 【Chemistry 1】 (In the formula, G 4 represents a protecting group for a hydrogen atom or a hydroxyl group, G 9 represents an ammonium ion, an alkylammonium ion, an alkali metal ion, a hydrogen ion, or a hydroxyalkylammonium ion, B c each independently represents the same or different nucleobase, R are each independently the same or different and each represents a hydrogen atom, a fluorine atom, or an OQ group; Q are each independently the same or different and each independently represent a tert-butyldimethylsilyl group, a methyl group, a 2-methoxyethyl group, a methylene group bonded to the carbon atom at the 4' position of ribose, an ethylene group bonded to the carbon atom at the 4' position of ribose, an ethylidene group bonded to the carbon atom at the 4' position of ribose, or a group represented by the following formula (1): 【Chemistry 2】 (In the formula, The bond marked with * indicates a bond with the oxygen atom of the OQ group. n represents an integer of 0 or more. represents a protecting group of Y's are independently the same or different and each represents an oxygen atom or a sulfur atom; m represents an integer of 2 to 300; W and X are defined as either (a) or (b) below: (a) When W is a hydroxyl group, X has the same definition as R above. (b) when X is a hydroxyl group, W is an OV group; V represents a tert-butyldimethylsilyl group or a group represented by the formula (1) above. However, at least one of the groups R, W, and X represents a hydroxyl group protected by a protecting group of the formula (1). When m is an integer of 3 or more, the nucleic acid oligomer represented by formula (3) is a nucleic acid oligomer in which a non-nucleotide linker may be incorporated in place of p nucleotides (wherein p is a positive integer satisfying the formula: m-1>p) between the 5'-terminal and 3'-terminal nucleotides. The present invention relates to a method for producing a nucleic acid oligomer represented by the following formula (4): 【Chemistry 3】 (In the formula, R' are each independently the same or different and represent a hydroxyl group, a hydrogen atom, a fluorine atom, a methoxy group, a 2-methoxyethyl group, or an OQ' group; Q' are each independently the same or different and each represent a methylene group bonded to the 4' carbon atom of ribose, an ethylene group bonded to the 4' carbon atom, or an ethylidene group bonded to the 4' carbon atom of ribose, Substituent G in Formula (4) 4 , G 9 , Y, B c and m are the same as those in formula (3), W 0 is a hydroxyl group, X 0 has the same definition as the R′ group above. When m is an integer of 3 or more, the nucleic acid oligomer represented by formula (4) is a nucleic acid oligomer in which a non-nucleotide linker may be incorporated in place of p nucleotides (wherein p is a positive integer that satisfies the formula: m-1>p) between the 5'-terminal and 3'-terminal nucleotides. A method for producing a nucleic acid oligomer represented by the formula:
2. The method according to claim 1 , wherein n in formula (1) is 0 or 1.
3. The method according to claim 1 , wherein n in formula (1) is 0.
4. The method according to claim 1 , wherein n in formula (1) is 1.
5. The method according to any one of claims 1 to 4, wherein the non-nucleotide linker is a linker having an amino acid backbone.
6. The method according to claim 5, wherein the linker having an amino acid skeleton has a structure represented by the following formula (A14-1), (A14-2) or (A14-3): 【Chemistry 4】 【Chemistry 5】 【Chemistry 6】 (In the formula, 5' and 3' represent the 5'-end and 3'-end of the nucleic acid oligomer, respectively.)
7. W is a hydroxyl group, X is an R group, and W 0 is a hydroxyl group, and X 0 The method according to any one of claims 1 to 6, wherein is an R' group.
8. The method according to any one of claims 1 to 7, wherein the fluoride ion source is a tetraalkylammonium fluoride.
9. The method according to any one of claims 1 to 8, wherein the fluoride ion source is tetra-n-butylammonium fluoride.
10. The method according to any one of claims 1 to 9, wherein the radical reaction inhibitor is a radical chain initiation inhibitor, a radical scavenger, or a peroxide decomposer.
11. The method according to any one of claims 1 to 9, wherein the radical reaction inhibitor is a radical scavenger.
12. The method according to claim 11, wherein the radical scavenger is a phenol-based antioxidant or a hindered amine-based light stabilizer.
13. The method according to claim 12, wherein the phenol-based antioxidant is a compound represented by the following formula (8): 【Chemistry 7】 (In the formula, R 10 , R 11 , R 12 , and R 13 are the same or different, and each represents a chain hydrocarbon group, a carbocyclyl group, a heterocyclyl group, an alkoxy group, an alkylsulfanyl group (the chain hydrocarbon group, the carbocyclyl group, the heterocyclyl group, the alkoxy group, and the alkylsulfanyl group may have one or more substituents), SiR 51 R 52 R 53 , amide group, C(O)R 61 , O.C.(O)R 61 , a hydroxyl group, or a hydrogen atom; R 51 , R 52 and R 53 are the same or different and each represents an alkyl group, an alkoxy group, or a hydrogen atom; R 61 represents a chain hydrocarbon group.)
14. The method according to claim 12, wherein the hindered amine light stabilizer is a compound represented by the following formula (12): 【Chemistry 8】 (In the formula, R 14 is O.C.O.R. 20 , N.H.R. 20 or a hydrogen atom, R 19 represents an alkyl group, an alkoxy group, an oxygen free radical, a hydroxyl group, or a hydrogen atom; R 15 , R 16 , R 17 , and R 18 are the same or different and each represents an alkyl group or a hydrogen atom; R 20 represents an open chain hydrocarbon group, a carbocyclyl group, a heterocyclyl group, an alkoxy group, or an alkylsulfanyl group (the open chain hydrocarbon group, the carbocyclyl group, the heterocyclyl group, the alkoxy group, or the alkylsulfanyl group may have one or more substituents), SiR 54 R 55 R 56 , an amide group, a hydroxyl group, or a hydrogen atom; R 54 , R 55 and R 56 are the same or different and represent an alkyl group, an alkoxy group, or a hydrogen atom.)
15. The method according to any one of claims 1 to 9, wherein the radical reaction inhibitor is a peroxide decomposer.
16. The method according to claim 15, wherein the peroxide decomposer is a phosphorus-based antioxidant or a sulfur-based antioxidant.
17. The method according to any one of claims 1 to 9, wherein the radical reaction inhibitor is a radical chain initiation inhibitor.
18. 18. The process of claim 17, wherein the radical chain initiation inhibitor is a metal deactivator or an ultraviolet light absorber.
19. The method according to any one of claims 1 to 18, wherein the amount of the radical reaction inhibitor used is 9 moles or less per mole of the number of moles obtained by multiplying the number of moles of the nucleic acid oligomer represented by formula (3) by the number of moles in which R in formula (3) is a group represented by formula (1).
20. The method according to any one of claims 1 to 19, wherein the ratio of the protecting group of formula (1) among R, W and X of the nucleic acid oligomer represented by formula (3) is 10% or more, and the nucleic acid chain length is 10 chain lengths or more.
